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Abstract
Current vesicular stomatitis virus (VSV)-based HIV vaccines require an optimal HIV envelope
immunogen to improve protection in vivo. Furthermore, the involvement of viral proteins, such as HIV
Nef, in the trafficking of HIV Env to sites of viral assembly remains poorly understood and may
provide additional insights for the design of a VSV-based HIV vaccine. We constructed new codonoptimized chimeric Env immunogens containing the signal sequence of honeybee melittin and the
transmembrane and cytoplasmic tail domains of SIV, Zaire Ebola, or VSV glycoproteins. We showed
that all chimeric Env immunogens had enhanced expression levels within producer cells. Utilizing
bimolecular fluorescence complementation for intracellular protein-protein interactions, we identified
a potential Env:Nef complex, which was disrupted by well-characterized Nef mutants. Overall, we
have generated new highly expressing chimeric HIV-1 Env immunogens prepared for testing in the
VSV vaccine platform and have shown evidence for a potential Env:Nef interaction within Env
trafficking pathways.
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Summary for Lay Audience
Over 36 million people suffer from Human Immunodeficiency Virus (HIV) and approximately 1.8
million new cases arise annually. While drugs exist to help treat symptoms, currently no vaccine is
available to prevent and combat the prevalent spread of infections. We aimed to improve upon a
vaccine designed by Dr. Chris Parks from the International AIDS Vaccine Initiative. This vaccine uses
a modified animal virus (VSV), which does not cause disease in humans, as a vehicle to safely deliver
a fragment of a surface protein from HIV termed Env. This HIV protein interacts with the body’s
immune system to stimulate production of antibodies that protect against future HIV infection. We
further improved and engineered the Env protein in multiple ways to enhance its protection abilities
by increasing its presence within the VSV delivery vehicle. Eventually, we plan to test the efficacy of
these new vaccines in mice and rabbits to select the best candidate. Finally, the most promising
candidates will be tested in rhesus monkeys to see if they can protect these animals against a similar
virus infection. In addition to improving the vaccine, we also studied the unaltered form of the Env
protein to better understand how it functions within our cells. We have found evidence supporting a
new interaction for Env protein, which has the potential to become novel targets for therapeutic
strategies against HIV infections. Based on our future studies on Env protein vaccine implementation
and function, we wish to use the knowledge from these studies to aid in humanity’s war to conquer
HIV.
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Chapter 1

1

Introduction

1.1 HIV and AIDS, a health concern of global importance
Since its discovery in 1983, human immunodeficiency virus (HIV) has resulted in approximately
32 million deaths and infected a total of 70 million individuals, earning it the title as one of the
greatest threats to global health1,2. In the absence of medical treatment, HIV infection leads to
acquired immunodeficiency syndrome (AIDS), which is characterized by the near complete
depletion

of

a

patient’s

CD4+

T-lymphocytes.

This

leaves

patients

significantly

immunocompromised and susceptible to opportunistic infections. Fortunately, the movement
towards global implementation of anti-retroviral therapy (ART) for HIV-infected individuals has
greatly helped to suppress the number of AIDS-related deaths3,4. Despite the effectiveness of ART,
1.7 million new people are infected with HIV per year, emphasizing the need for an effective HIV1 vaccine1. Although there have been multiple attempts at the development of vaccines, none have
provided sufficient protection in clinical trials to date, a result that could be partly attributed to the
vast genetic diversity of HIV-1.

1.1.1 HIV-1 diversity
HIV-1 is a highly diverse virus and can be classified into four groups: M, N, O, and P. Group M
is responsible for the majority of infections worldwide, and can be further divided into nine
genetically distinct subtypes A, B, C, D, F, G, H, J, K, and various circulating recombinant forms
(CRFs)5,6. Genetic diversity between Group M subtypes ranges from 20-30%, with intra-subtype
genetic diversity around 12%7,8. In addition to the highly diverse HIV-1 groups (M-P) and Group
M subtypes, HIV-1 is also highly variable within a single host, known as the viral quasispecies9.
This additional level of variability arises from a rapid rate of virion production combined with the
error prone HIV-1 reverse transcriptase enzyme. The quasispecies or viral swarm that arises
creates ample opportunities for HIV-1 mutants that are able to avoid recognition from our immune
system. As the only exposed component on HIV-1 particles, the HIV-1 Envelope protein is the
main target of the host humoral immune response. In response, the HIV-1 env gene is the most
diverse gene in the genome.
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1.1.2 HIV-1 genome and proteins
HIV-1 possesses a single-stranded, positive sense RNA genome of approximately 9.7 kilobases in
size10. As shown in Figure 1A, the genome contains nine open reading frames (ORFs) which
produce a total of 15 proteins. The production of these proteins is accomplished through alternative
RNA splicing, ribosomal frame shifting, and cleavage by viral and cellular proteases11,12. The three
major genes, gag, pol, and env are synthesized as polyproteins and encode the major structural and
enzymatic proteins. The tat and rev genes encode for the HIV-1 regulatory proteins that facilitate
the regulated expression of other HIV-1 genes. Lastly, the vif, vpr, vpu, and nef genes encode for
the HIV-1 accessory proteins which enhance replication and infectivity. Each viral protein plays
an important role during the HIV replication cycle.

The HIV capsid, nucleocapsid, and matrix structural proteins are produced as a Gag polyprotein,
which are released after cleavage by the HIV protease enzyme during virion maturation. A
ribosomal frame-shift at the 3’ end of gag mRNA during translation allows for the production of
a gag-pol polyprotein precursor, which includes the Gag proteins as well as HIV protease,
integrase, and reverse transcriptase enzymes of Pol11,13.

The HIV Env protein is essential for the infection of target cells and is co-translationally
translocated into the ER as the precursor polyprotein, gp160. Env travels through the cellular
secretory pathway, where it is glycosylated, trimerizes, processed into the gp120 and gp41 subunits
by the cellular protease furin, and subsequently delivered to the plasma membrane14. The mature
functional gp120-gp41 trimers then traffic to sites of viral assembly for incorporation into budding
virions. Interestingly, HIV incorporates only ~7-14 glycoprotein trimers per virion. This amount
is considerably lower than the related simian immunodeficiency virus (SIV), which has
approximately 80 Env trimers per virion15. A detailed description of the Env components and
structure will be discussed in section 1.2 of this thesis.

The HIV-1 regulatory proteins Tat and Rev are each produced from complete mRNA splicing of
HIV-1 mRNA transcripts. Tat functions to enhance HIV-1 mRNA transcription after the proviral
DNA has been integrated in the host cell genome16. Rev mediates the nuclear export of unspliced
or partly spliced viral mRNA transcripts containing a target secondary structure, termed the rev-
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response element (RRE). In the absence of Rev, transcripts containing the RRE will not be
exported from the nucleus and are degraded by host factors, which would prevent the expression
of the main HIV-1 structural proteins17.

The HIV accessory proteins, Vpr, Vif, Vpu, and Nef play important roles in the pathogenesis of
HIV in vivo by optimizing the cellular environment of infected cells for HIV replication or
enhancing virus protein production. Vpu and Nef affect the expression or localization of various
cellular proteins in a post-translational manner. Vpu interacts directly with the cellular protein
CD4, the receptor for HIV Env, in the ER and directs it for degradation to prevent its interaction
with the HIV Env protein18. Nef has a plethora of functions, such as downregulating cell surface
receptors, regulating T cell activation, and enhancing viral infectivity. The ability of Nef to affect
such a diverse array of cellular proteins results from its many interacting domains and its ability
to hijack proteins that regulate subcellular trafficking. A detailed description of Nef’s most wellstudied functions will be reviewed in section 1.2.2 of this thesis.

1.1.3 HIV-1 replication cycle
The HIV-1 replication cycle can be divided into seven stages, beginning with the attachment of a
free virion particle to the host cell and ending with the maturation of newly produced HIV virions
arising from a host cell (Figure 1B). First, HIV-1 binds to target cells through the attachment of
Env to the cellular receptor CD419. Upon interaction with a co-receptor, CCR5 or CXCR4,
structural changes in the HIV-1 Env protein causes fusion of the viral and cellular lipid envelopes
releasing the viral core into the cell. Next, the HIV-1 RNA genome is reverse transcribed into
dsDNA and shuttled into the nucleus by the HIV-1 Reverse Transcriptase and Vpr. Once in the
nucleus, the HIV proviral genome is integrated into the host cell genome by HIV-1- Integrase.
Now that the genome is integrated, expression of the HIV-1 genes can occur in the target cell via
host machinery.
HIV-1 transcription is mediated by a single promotor in the 5’ LTR (Long terminal repeat), which
generates a 9kb primary transcript encoding all nine HIV-1 ORFs. This primary transcript contains
numerous splice donor and acceptor sites allowing it to be spliced into more than 30 mRNA
transcripts by host spliceosomes. The expression of the HIV-1 genes occurs as a stepwise process,
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with the expression of early and late genes dependent on their requirement for the HIV-1 Rev
protein. Initially, the primary viral transcripts are completely spliced by the normal cellular
splicing machinery to produce the early viral gene products, Tat, Rev, and Nef20. These accessory
proteins begin to manipulate and optimize the cellular environment for the production of new HIV
virions. As the amount of HIV Rev increases, it interacts with and exports viral RNAs that contain
an RRE (i.e. gag, gag-pol, and env transcripts), which allows for the production of the HIV
structural and enzymatic proteins, and full length RNA transcripts, tipping the focus of the
lifecycle towards the production of new virions21.

As the replication cycle transitions to the production of late genes, these various proteins must
traffic to the plasma membrane for viral assembly. The HIV-1 Gag and Gag-Pol polyproteins
coordinate the assembly of HIV particle formation and budding. It has been shown that the sole
expression of the Gag or Gag-Pol polyprotein is sufficient for the production of HIV particles that
bud from the plasma membrane. Gag and Gag-Pol polyproteins are produced within the cytoplasm,
where some will associate with dimerized HIV-1 RNA, and then traffic to lipid rich platforms22.
Here, the Gag and Gag-Pol polyproteins coordinate the assembly of the other HIV proteins. The
HIV-1 accessory protein Vpr is incorporated into budding virions to transport the preintegration
complex into the nucleus of newly infected cells. Lastly, Env is required to produce virions with
the ability to infect new target cells. Produced cotranslationally into the ER membrane as a
polyprotein precursor, HIV-1 Env undergoes maturation and modifications in the cellular
trafficking compartments as it traffics to sites of viral assembly. As sufficient numbers of the viral
proteins accumulate, Gag particles recruit the cellular ESCRT (endosomal sorting complexes
required for transport) machinery, which terminates Gag polymerization and catalyzes the release
of an immature virion with a cellular-derived lipid membrane23. Lastly, HIV Protease present in
newly budded virions becomes activated and cleaves the major constituents of Gag. The resulting
structural changes provide the virion with the ability to infect target cells, thus acting as the switch
to become an infectious particle. A summary of the HIV-1 replication cycle is shown in Figure
1B.
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A

B

Figure 1. Schematic of HIV-1 genome and replication cycle. (A) The HIV-1 genome consists
of nine open reading frames and encodes fifteen proteins. The genome is approximately 9.7 kb and
contains all the essential HIV enzymatic, structural, and accessory proteins for viral replication.
Image unaltered and retrieved from Thomas Splettstoesser (www.scistyle.com) - Own work, CC
BY-SA 3.0, https://creativecommons.org/ licenses/by-sa/3.0/. (B) 1. The replication cycle of HIV1 begins with the fusion with a target cell. 2. The HIV core enters the cytoplasm, releasing the preintegration complex. 3. The viral DNA is reverse transcribed from RNA into double stranded
DNA. 4. The pre-integration complex enters the nucleus and is integrated into the host genome. 5.
The HIV genome is transcribed and translated, expressing the viral proteins. 6. The HIV proteins
enact their functions and HIV Gag coordinates the assembly of new virus particles. 7. Newly
budded particles mature due to cleavage of internal proteins, producing infectious particles. Image
unaltered and retrieved from NIAID24.
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1.2 HIV-1 Envelope
The HIV-1 Envelope protein plays a major role in the HIV-1 replication cycle by mediating virion
entry into target cells. As the only HIV-1 protein expressed on the plasma membrane and HIV-1
particles visible to the immune system, Env is a desirable target for vaccination. Unfortunately,
because of selective pressure, Env has evolved multiple mechanisms by which to combat the host
immune response. These mechanisms include: 1) presence of the glycan “shield”, 2) high sequence
variability in the exposed regions, 3) hiding immunogenic epitopes with conformational changes,
and 4) maintaining low cell surface and viral particle levels of Env7,25–27. An effective vaccine
design must overcome these barriers and requires a deeper understanding of subcellular Env
processing.

The HIV Env polyprotein precursor, gp160, is co-translationally produced into the endoplasmic
reticulum (ER), as a type I integral protein. Concurrent with translation, the luminal portion of
gp160 is heavily glycosylated at N-linked glycosylation sites, forming the basis of the Env glycan
“shield”25. These glycans undergo further processing in the trans-Golgi network (TGN), becoming
highly complex mannose-based carbohydrates and as a whole conceal many immunogenic sites of
mature Env. During transit to the plasma membrane, gp160 oligomerizes mainly into trimers. Each
gp160 component is subsequently cleaved by the cellular protease furin into gp120 and gp41
proteins to become the mature heterotrimeric Env protein14. Gp41 acts as the foundation of Env
trimers, having an extracellular, transmembrane, and intracellular domain, while gp120 is entirely
extracellular and is attached to the gp41 extracellular domain via non-covalent interactions. The
overall trafficking of Env is highly regulated by trafficking motifs in the gp41 cytoplasmic tail,
which maintain low levels of Env on the plasma membrane and in HIV particles. It is believed
HIV evolved this mechanism to avoid recognition by the host immune response27. With low levels
of Env on the surface of infected cells, or virus particles, it is extremely difficult for the host
immune system to generate an effective immune response. The structure and function of gp120 is
described below, outlining the other mechanisms by which Env evades immune recognition.

1.2.1 Gp120
Gp120 consists of five conserved regions (C1-C5) with interspersed variable loop regions (V1V5)28. The tertiary structure of gp120 is held together by numerous disulfide bonds, which help to
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make up four main components of gp120: the inner domain, outer domain, bridging sheet, and
third variable loop (V3) (Figure 2A). The outer domain is mostly composed of variable regions
coated with glycosylation and this forms a portion of the CD4 binding site (CD4bs)28.
Glycosylation and the high sequence variability of the outer domain allows for impressive immune
evasion abilities. The inner domain of gp120 consists largely of C1-C5 and serves to interact with
gp41 and form a portion of the discontinuous CD4bs. The bridging sheet is composed of antiparallel β-pleated sheets and links the inner and outer domains of Env. It also contributes to the
formation of the CD4 binding site and coreceptor binding site. Lastly, the V3 loop, the most distal
part of gp120 in relation to the plasma membrane, forms the coreceptor binding site in conjunction
with the bridging sheet (Figure 2B). The regions of gp120 that HIV-1 utilizes for entry into a host
cell, namely the CD4bs and coreceptor binding site, are discontinuous regions that are only formed
due to conformational changes in Env29. Interestingly, Env can exist in three conformational states:
state 1 (closed or unbound to CD4), state 2 (intermediate), and state 3 (open or CD4 bound). HIV1 Env exists in equilibrium between each of these conformations. In the absence of external factors,
53% of Env will exist in a closed conformation, 19% in an intermediate conformation, and 28%
in an open conformation26. In the closed conformation, the CD4 and coreceptor binding sites are
not formed. During interaction of Env with CD4, each Env protomer transitions to an intermediate
state, which then favours the transition to the CD4 bound state26. In this state, the bridging sheet
and V3 loop are optimally positioned to interact with the CCR5 or CXCR4 coreceptor. Binding to
CCR5 or CXCR4 would then initiate the conformational changes of gp120 and the gp41
extracellular region required for fusion of the viral and cellular membranes. Despite the numerous
immune evasion mechanisms utilized by HIV-1, there is an array of antibody responses against
the HIV-1 Env glycoprotein, some of which are strain specific and others of which can neutralize
a broad range of HIV-1 strains.
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A
Variable
V3
Loop

B
CCR5
binding site
Bridging
Sheet

CD4bs
Outer
Domain

Inner
Domain

Figure 2. Schematic representation of gp120. Crystallization structures of gp120 (HIV YU2
strain) solved in complex with CD4, the N-terminus of CCR5 and the monoclonal antibody 412d
(PDB: 2QAD)30. CD4 and 412d are not shown. (A) The inner domain (pink), outer domain (teal),
bridging sheet (yellow), and variable loop (orange) are shown. (B) The CD4 binding site (CD4bs,
yellow mesh) is composed of the inner and outer domains and the bridging sheet. The CCR5
binding site is composed of the bridging sheet and V3 loop (blue mesh). Images were edited using
PyMol.
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1.2.2 Anti-HIV-1 Ab responses
The humoral response elicited against HIV-1 Env can be classified into three antibody (Ab)
categories based on neutralization ability of Env-mediated entry31. First, non-neutralizing Env Abs
are frequently produced against HIV-1 Env in natural infection. These Abs have specificity for
epitopes on Env that do not interfere with Env function. Despite this, these Abs still have anti-viral
activity on HIV-1 particles and HIV-infected cells31. Non-neutralizing Abs bound to HIV-1
particles possess the ability to induce Fc fragment-mediated phagocytosis by antigen presenting
cells. Acidification of phagosomes destroys HIV virions and allows the display of viral peptides
for T lymphocyte activation32. Binding of non-neutralizing Abs to Env on infected cells can also
trigger antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells, which leads to the
death of the HIV-infected cell33. Anti-HIV Env ADCC-inducing Abs were shown to be the major
correlate of protection in the RV144 vaccine study, thus supporting their importance for future
HIV-1 vaccines34.
The second group of anti-HIV Env Ab responses is strain-specific neutralizing Abs, mainly
targeted at highly variable regions of Env and these prevent viral entry. These Abs are elicited
early on in HIV infection and are the mechanism by which HIV-1 continually avoids Ab control.
Because these variable regions are immunodominant and highly variable, the continuous
accumulation of mutations within these epitopes allows HIV-1 to escape immune surveillance31.
It is important to note that neutralizing Abs may also be able to act in Fc-mediated phagocytosis
or ADCC, as these mechanisms are not mutually exclusive35,36.
The third group of anti-HIV Env Ab responses is Abs that are able to neutralize a wide range of
HIV strains, known as broadly neutralizing Abs (bNAbs)31. These Abs target well conserved
epitopes in Env, regions which play essential roles in the function of Env and thus maintain
relatively similar sequences and structure. The production of bNAbs occurs in 10-20% of late HIVinfected patients37. This supports the possibility of engineering an Env immunogen able to induce
bNAbs production through vaccination. Due to their wide neutralizing abilities, bNAbs and their
specificities have been studied extensively. The specificity of any known anti-HIV bNAbs is
directed at one of five different regions of Env: CD4 binding site, V1/V2 loops, V3-glycans,
gp120-gp41 interface, and the gp41 membrane proximal external region (Figure 3)38–41. BNAbs
can be grouped depending on the conformation of Env in which they are able to bind to their
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epitope. Most bNAbs with specificity to the CD4 binding site, V1/V2 loop, and V3-glycan require
a closed Env conformation for neutralization. In contrast, bNAbs that target the gp120-gp41
interface require a conformational change of Env to the intermediate or open conformations, which
allows for recognition within the membrane proximal region of the gp41 extracellular domain.
Many bNAbs in both classes have potent neutralization breadths. In the absence of modifications,
HIV Env proteins will transition between the various states, which decreases its ability to elicit a
strong bNAb response against a particular epitope. Thus, many studies focus on producing an Env
immunogen that favours one state over the other to expose bNAb epitopes, while maintaining the
correct structure of Env32,42. Recent studies by the Arts lab on a naturally occurring Env variant
with a more open conformation shows promise for immunogen design43. This immunogen will be
further discussed in relation to vaccine design in section 1.4 of this thesis.
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Figure 3. Anti-HIV-1 Env broadly neutralizing antibody specificities. Left: HIV-1 Env
depicting the five different regions that broadly neutralizing antibodies (bNAbs) are known to
target. Numerous examples of bNAbs and their site specificity are provided. Right: The
conformation of HIV-1 Env preferred for the binding of the bNAbs VRC01 (State 1) and Z13e1
(states 2/3). Image retrieved from Flemming et al26, Mary Ann Liebert, Inc. New Rochelle, NY
(copyright permission granted).
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1.2.3 The potential role of HIV Nef in Env trafficking
The complex trafficking itinerary of HIV-1 Env is highly regulated by the gp41 cytoplasmic tail
(CT), and has been hypothesized to have evolved to maintain low levels of Env on the plasma
membrane and HIV particles for immune evasion44,45. Even though the pathway between Env
synthesis in the ER and subsequent trafficking to the plasma membrane is poorly characterized,
Env endocytosis is accomplished through interactions of the gp41 CT and key regulators of cellular
trafficking, such as the adaptor protein (AP) complexes46–48. The AP complexes are
heterotetrameric protein complexes which mediate intracellular membrane trafficking along
endocytic and secretory transport pathways49. Upon recognition of cargo proteins, the AP
complexes initiate the formation of vesicles and act as carriers to mediate the transport of cargo
proteins between cellular organelles and the plasma membrane. Two of the most important AP
proteins in Env trafficking, AP-1 and AP-2, function in specific regions of the cell: AP-1 mediates
the bidirectional trafficking of cargo proteins between the TGN and recycling endosomes, whereas
AP-2 plays a role in clathrin-mediated endocytosis from the plasma membrane49. The ability of
gp41 to exploit AP-1 and AP-2 dependent trafficking relies on two motifs within its cytoplasmic
tail, a membrane proximal YxxΦ motif (Y710SPL, based on HIV NL4-3) and a C-terminal
dileucine (L850L851) motif, both of which have been shown to mediate interaction with AP-1 and
AP-2 (figure 4)46,47,50. Via AP-2 interactions with gp41 motifs, HIV Env are endocytosed leading
to decreased surface expression. Interestingly, these motifs also appear to be redundant, as deletion
of only one or the other has little effect on endocytosis, whereas mutation of both completely
ablates Env endocytosis. It’s been hypothesized that HIV Env maintained this redundancy because
the endocytosis of Env from the cell surface is essential for avoiding immune system recognition44.
In addition to AP-2, the same gp41 CT motifs have been shown to interact with AP-1 for
intracellular trafficking; however, the precise location of the Env:AP-1 interaction and its role in
Env trafficking is relatively uncharacterized46. In addition to these motifs, the diaromatic (Y800W)
motif in the gp41 CT was recently reported by Kirschman et al (2018) to play an essential role in
trafficking Env to sites of viral assembly through recycling endosomes by interacting with Rab14
and FIP1C, regulators of intracellular membrane trafficking51. In addition to these wellcharacterized motifs, the gp41 CT contains many other motifs whose functions remain elusive and
multiple pathways of Env trafficking between membrane bound organelles (ER, TGN) and the
plasma membrane remain to be determined.
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HIV-1 Nef is a multifunctional protein that hijacks important host trafficking proteins to alter the
expression of many cellular surface receptors. Nef enacts its functions by acting as an intermediary
between cargo proteins and trafficking regulators. Specifically, it interacts with AP complexes and
phosphofurin acidic cluster sorting proteins (PACS-1/-2) to enhance viral replication52–54. Two of
the best studied functions of Nef are its ability to downregulate CD4 and MHC-I cell surface
expression, and both these processes exploit Nef’s interactions with these cellular regulators of
protein trafficking. Initiation of CD4 downregulation from the cell surface requires Nef to bind to
the CT of CD4 (Nef residues involved, W57L58) linking it to AP-2 (EXXXLL160-165, DD174,175) and
causing the formation of a Nef:AP‐2:CD4 ternary complex55–58. This complex triggers
internalization of CD4-containing clathrin-coated vesicles to early endosomes, leading to its
eventual degradation in lysosomes. As for its MHC-I downregulation function, Nef hijacks AP-1,
PACS-1, and PACS-2 among other trafficking regulators. PACS-2 binds Nef by interaction with
the Nef motifs, EEEE62-65, P78, W113, Y120. This causes a re-localization to the TGN, where Nef
can interact with a Src family kinase member (P72,75,78, and others) containing an SH3 domain to
initiate a signaling cascade that causes endocytosis of MHC-I into early endosomes. Nef within
early endosomes then recruits AP-1 (EEEE62-65) via PACS-1 (EEEE62-65, P78, W113, Y120) to
transport endocytosed MHC-I to the TGN and prevent its recycling back to the plasma
membrane52,59–62. From the TGN, a tripartite complex of Nef:MHC-I:AP-1 (P72XXP75 binds MHCI, EEEE62-65 binds AP-1) transports MHC-I molecules to the early endosome and forces them to
the lysosome for destruction, rather than recycling to the PM54. Furthermore, newly synthesized
MHC-I in the TGN that has not yet reached the PM is also diverted to lysosomes for degradation.
As mentioned above, HIV Env and Nef both rely on interactions with key regulators of cellular
trafficking, such as AP-1 and AP-2. Although the endocytosis of Env from the PM via AP-2 is
well studied, many other stages of Env trafficking to sites of viral assembly require further
investigation. Specifically, AP-1 has been shown to interact with Env via two trafficking motifs;
however, where the Env:AP-1 interaction begins and the role that this interaction plays in overall
Env trafficking is not well known46,47,49. As a regulator of protein trafficking with a key role in
optimizing the cellular landscape, it is possible that Nef may interact with Env in a multiprotein
complex including AP-1 or AP-2 to support Env trafficking to sites of viral assembly, or
potentially retaining it intracellularly as an additional immune evasion mechanism. The following
panel of four key Nef mutants will be utilized to determine the possible mechanisms by which Nef
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interacts with Env and how this interaction can also elucidate the potential role of AP and PACS
proteins in this trafficking process. More specifically, utilizing the Nef-E4A mutant (EEEE62-65 →
AAAA62-65) with altered MHC-I downregulation will allow us to determine the involvement of the
AP-1 or the PACS proteins in Env trafficking53,62,63. Similarly, the Nef-AxxA mutant (P72P75 →
A72A75) also perturbs MHC-I downregulation, but will reveal if binding to Src family kinases is
required for interaction with Env53,59,63. Alternatively, the LL164/165AA or DD174/175AA Nef
mutants exhibit altered CD4 downregulation and will determine the involvement of AP-254,63,64.
Overall, the reliance of Env trafficking on the AP family members and the interactions of Nef with
the same subset of trafficking regulator proteins emphasizes the potential involvement of Nef in
Env trafficking.
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Figure 4. Schematic representation of the gp41 cytoplasmic tail and trafficking motifs. (A)
The HIV-1 NL4-3 gp41 cytoplasmic tail amino acid sequence. The two endocytic motifs,
membrane proximal YxxΦ (Y710SPL, red) and C-terminal dileucine (L850L851, blue), are depicted.
The diaromatic Y800W motif (yellow). The non-endocytic YxxΦ (Y766HRL, green), and dileucine
motifs (blue) are also shown. (B) The HIV-1 NL4-3 Nef amino acid sequence depicting various
domains (red) required for protein-protein interactions. The amino acid changes of wellcharacterized Nef mutants: Nef-E4A (green), Nef-AxxA (blue), Nef-LL164/165AA (purple), and
Nef-DD174/175AA (pink) are depicted. Both sequences are sourced from HIV-1 clone pNL4-3,
subclone 4.20 (Genbank: U26942.1).
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1.3 HIV-1 Vaccine
Since the discovery of HIV in 1983, there have been many attempts to produce a protective
vaccine. However, only four vaccine candidates have been tested for efficacy in humans. The first
vaccine, AIDSVAX, tested in 1995, consisted of an immunization with recombinant monomeric
gp120 proteins. The goal of the vaccine was to generate an antibody response that would remove
the gp120 components from HIV viral particles and thus disable the virus. Unfortunately, it
induced a poor antibody response against trimeric Env65,66. Roughly a decade later, the STEP trial
attempted to achieve CD8+ T cell-mediated protection by immunizing individuals with a
replication-incompetent recombinant adenovirus serotype 5 (rAD5) vector encoding HIV Gag,
Pol, and Nef. Not only was this vaccine unable to provide enhanced protection to HIV, but certain
subgroups of vaccine recipients exhibited increased risk of HIV infection, resulting in termination
of the STEP study67. The subsequent trial, referred to as MVTN505, utilized a DNA prime with
HIV gag/pol/nef/env and boosted with a rAD5 vector encoding HIV Gag, Pol, and Env. Again, the
study was halted, as it did not provide protection from HIV infection67. The fourth trial, RV144,
conducted in Thailand, showed 31% efficacy, and therefore has been the most promising HIV
vaccine candidate. Interestingly, it was a combined vaccine with a primary injection of replicationdefective canarypox vector (ALVAC) encoding HIV Gag, Pol, and Nef and a boost of a
recombinant HIV gp120 from the initial AIDSVAX study68. The main protective outcome of
protection for this vaccine was the production of non-neutralizing IgG antibodies against the
V1/V2 region of gp120. Although bNAbs were rarely observed in this study, this does not preclude
their potential value in a future vaccine34. In fact, passive immunization of bNAbs in macaques
has provided the best protection against SHIV (SIV/HIV virus) infection to date69,70. Overall, these
studies have provided valuable information for the generation of new, more effective HIV
vaccines.
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1.3.1 Replication competent vesicular stomatitis virus platform for an HIV-1
Vaccine
A particularly powerful vaccine type are vaccines produced using replication competent
recombinant viral vectors71. This process which entails to genetically engineer a non-pathogenic
virus to express the glycoprotein from a virus of interest. These recombinant vaccines can infect
and replicate in host cells, which allows for a strong engagement of both host cellular and humoral
immune responses71. A widely used replication competent vaccine platform is one that uses the
vesicular stomatitis virus (VSV), a member of the Rhabdoviridae family72–75. VSV contains an
approximately 11kb negative-sense RNA genome, which encodes five viral proteins, the
nucleocapsid protein (N), the phosphoprotein (P), the matrix protein (M), the glycoprotein (G),
and the large protein (L)76. VSV can infect livestock such as cattle, horses, and swine; however,
infrequent infection of humans causes asymptomatic or mild flu-like symptoms77. Furthermore,
VSV is an attractive replication competent recombinant vaccine platform due to its rapid
replication rate and its ability to easily incorporate foreign glycoproteins, or be pseudotyped, upon
the budding process78. The Indiana VSV serotype has been used as a vaccine platform in the
generation of the recombinant VSV Zaire Ebola virus vaccine (rVSV-ZEBOV), which encodes
the Ebola virus glycoprotein (EBOV GP) in place of the VSV glycoprotein (VSV-G). This
construct allows for the generation of an immune response against Ebola virus (Figure 5)75. It is
also safe to administer to humans, has shown efficacy in protecting against Ebola in clinical trials,
and is currently being used in the Ebola virus outbreak in the Democratic Republic of Congo73,79.
Consequently, the use of the VSV platform for the generation of an HIV-1 vaccine soon followed.
VSVΔG-Env.BG505, developed by Dr. Chris Parks of the International AIDS Vaccine initiative,
is a promising HIV-1 vaccine candidate, as it provided 67% protection in a non-human primate
model of infection80. In place of the natural VSV-G gene, this vector encoded a chimeric HIV-1
Env protein with regions of Env replaced with the signal peptide, transmembrane, and cytoplasmic
tail regions of VSV-G. Despite the impressive protection observed, the vector induced only antiEnv binding antibodies with minimal neutralizing antibodies, was dependent on CD4+/CCR5+
cells for replication in vivo, and had low surface expression of chimeric Env on the VSV vector75.
Therefore, it cannot be assumed that the encoded chimeric HIV-1 Env/VSV-G gene represents the
most ideal Env immunogen.
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Figure 5. Schematic of current rVSVΔG-ZEBOV vaccine and rVSVΔG/HIVEnv vaccines.
(A) The wildtype VSV genome is shown with all genes. For generation of the rVSVΔG-ZEBOV
vaccine, the VSV-G gene was replaced with the full-length EBOV GP gene. Below is an image
depicting a rVSVΔG-ZEBOV vaccine particle. (B) A schematic showing the rVSVΔG/HIVEnv
vaccine construct containing a chimeric HIV-1 gene replacing the VSV-G gene. Below, is an
image depicting a rVSVΔG/HIVEnv vaccine particle. Image retrieved from Racine et al (2017)
AIDS and research therapy 14:5575.
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1.3.2

Challenges in developing a VSV-based HIV vaccine

1.3.2.1 Low levels of HIV-1 Env on VSV particles
HIV-1 is unique in the fact that, compared to other enveloped viruses, it incorporates very low
levels of its glycoprotein, Env, on the surface of virus particles. While HIV particles often have 714 Env trimers, closely related SIV particles often incorporate around ten-fold more of their
glycoprotein27. Furthermore, VSV particles incorporate upwards of 300 VSV-G trimers, despite
having a similar particle size to HIV75. This characteristic of wildtype HIV Env has been shown
to carry over when packaged within VSV particles81. This low level of Env on VSV particles
represents a significant roadblock for the production of a highly immunogenic vaccine. In contrast,
VSV-G is able to efficiently pseudotype HIV particles. The poor ability of HIV Env trimers to
pseudotype VSV particles has been shown to be due to trafficking signals in the HIV Env
cytoplasmic tail81. As previously described in section 1.2.2, the cytoplasmic tail of viral
glycoproteins is often the major determinant of cellular interacting partners, cell surface
expression, targeting to sites of viral assembly, and ultimately glycoprotein levels in virus
particles27. All these factors likely contribute to the differential pseudotyping abilities of HIV Env
and VSV-G for the each other’s virus particle; however, it is unclear how EBOV GP can efficiently
pseudotype VSV particles, as observed in the rVSVΔG-ZEBOV vaccine73,79. Although HIV-1
Env/VSV-G chimeras, as utilized by the International AIDS Vaccine Initiative (IAVI), enhanced
incorporation levels in VSV particles, the amount of Env/VSV-G incorporated is still much lower
than wildtype VSV-G78,81. Overall, these Env/VSV-G chimeras are not ideal and could be
improved75. Alternatively, the trafficking components of other viral glycoproteins may produce a
more optimal chimeric HIV Env immunogen. For example, EBOV GP is able to efficiently
pseudotype VSV particles in the rVSVΔG-ZEBOV vaccine in the absence of any
modifications73,79. SIVmac239 and HIV-1 are highly related, but SIVmac239 particles incorporate
roughly ten-fold more glycoproteins during viral budding27,82. During propagation in mammalian
cells, truncated SIVmac239 Env is able to efficiently pseudotype HIV particles27. Therefore,
producing new chimeric HIV-1 Env proteins with the transmembrane and cytoplasmic tail of
EBOV GP or the truncated SIVmac239 Env represent potential solutions for enhanced Env
expression on the VSV particle.
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In addition to altering the HIV-1 Env transmembrane and cytoplasmic tail domains, altering the
HIV Env signal peptide may also allow for enhanced expression of a chimeric Env on VSV vaccine
particles. The HIV Env signal peptide has been shown to slow the folding and intracellular
transport of HIV-1 Env, which contributes to low levels of mature Env on the cell surface83. To
avoid this, it has been shown that replacing the HIV-1 Env signal peptide with an exogenous signal
peptide can enhance Env surface expression in producer cells. For example, the Kang lab has
shown that replacing the HIV-1 Env signal peptide with the signal peptide of the honeybee melittin
protein, which enhances the translocation of HIV Env into the ER, greatly enhances Env
expression while maintaining Env glycosylation84,85. Thus, alteration of the HIV-1 Env signal
peptide represents a potential solution for enhancing Env expression on VSV particles.
While the design of chimeric Env proteins is important in the attempt to generate vaccine
candidates, we believe it is equally important to gain a better understanding of the HIV-1 Env
cellular trafficking pathways. As mentioned previously, many of the host proteins that regulate
HIV Env trafficking, including AP-1 and AP-2, are exploited by HIV Nef to mediate its
functions54. Given that HIV Nef may play a role in the trafficking of Env to sites of viral assembly,
investigating the role of HIV Nef in Env trafficking may provide additional insights into the
rational design of a VSV-based HIV vaccine.

1.3.2.2

Identifying the ideal Env immunogen

In addition to the suboptimal incorporation of chimeric HIV-1 Env on the VSV vector, the ideal
HIV-1 Envelope for inducing immune responses also remains elusive. Generally, most groups
choose to use a native Env sequence of a laboratory or primary HIV-1 strain, which is most often
present in the closed conformation75. In this conformation, Env usually elicits non-neutralizing,
anti-Env binding antibodies, which provide limited protection in animal studies75. Although no
HIV vaccine has resulted in the production of bNAbs to date, the generation of bNAbs remains an
ideal goal of immunization, because passive transfer of bNAb to non-human primates in an
infection model has provided the best immune-related protection70. BG505 gp140, derived from
the subtype A BG505 Env used in the IAVI vaccine, has been shown to express multiple bNAb
epitopes and represented an ideal candidate for the IAVI vaccine32.
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Alternatively, the Arts lab has previously described a naturally occurring, low frequency,
polymorphism (N425K) in the Env of subtype A HIV-1 A74, which shows potential for eliciting
bNAbs43. Preliminary studies of the A74 N425K gp120 in the context of the HIV-1 NL4-3 genome
demonstrated that this Env has enhanced viral replicative fitness, a higher binding affinity for CD4,
and enhanced entry kinetics. These characteristics are believed to be a consequence of A74 N425K
Env primarily existing in an open conformation43. A74 N425K Env is a promising candidate to
serve as the basis for generating new Env immunogens, because it originates from a natural source
and likely preserves the proper structure of Env epitopes. Therefore, use of A74 EnvK425 in the
VSV vector may allow for the generation of bNAbs that could provide strong levels of protection.

1.3.2.3 The VSVΔG.HIV.Env vector relies on CD4+/CCR5+ cells for replication
The IAVI VSVΔG-Env.BG505 vaccine relies on CD4+/CCR5+ cells for production in vitro and
vector propagation in vivo, due to the tropism of the chimeric Env protein. This makes it difficult
to propagate in vitro and raises the concern that the protection observed in the macaques tested by
IAVI may be simply due to a depletion of infectable CD4+/CCR5+ cells86. The EBOV GP, which
is known to be efficiently incorporated into VSV particles, utilizes a widely expressed cholesterol
transport protein for entry, providing broad cellular tropism and allowing for easy propagation of
the VSVΔG-ZEBOV in vitro87,88. Additionally, the EBOV GP can direct the infection of antigenpresenting cells which play key roles in inducing immune responses89. Thus, by directing infection
of these cells, such as dendritic cells and macrophages, the EBOV GP may also enhance the
immunogenicity of the VSV-HIV vaccine. Therefore, cloning the full-length EBOV GP in the
VSV vector alongside an HIV Env chimera, will eliminate the reliance of replication solely on the
HIV Env protein via CD4+/CCR5+ cells and may enhance vaccine immunogenicity.

1.4 Project rationale
In summary, HIV-1 represents one of humanity’s greatest challenges and, in the absence of a cure,
the number of infected individuals continues to rise. The prevention of initial HIV-1 infection
through vaccination remains the ideal goal. Despite numerous efforts, no HIV vaccine has been
able to provide satisfactory protection in human clinical trials. One of the most desired outcomes
for an HIV vaccine is the induction of broadly neutralizing antibodies, which could protect
individuals from infection by a multitude of HIV-1 viruses31. Unfortunately, certain characteristics
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of the HIV-1 Env protein have made this unattainable thus far, which include the gp120 glycan
“shield”, and low cell surface and virus particle levels of HIV Env due to regulation by the gp41
cytoplasmic tail27,28,90.
The replication competent vaccine candidate produced by the IAVI, VSVΔG-Env.BG505, aimed
to solve these Env-related issues by utilizing a chimeric Env immunogen containing the signal
peptide, transmembrane, and cytoplasmic tail domains of VSV-G. Despite providing 67%
protection in a non-human primate model of infection, the vector induced only anti-Env binding
antibodies and limited neutralizing antibodies, had a reliance on CD4+/CCR5+ cells for replication
in vivo, and had low surface expression of chimeric Env on the VSV vector75,80,86. Therefore, we
cannot assume the chimeric HIV-1 Env/VSV-G gene represents the ideal immunogen, or that the
VSVΔG-HIV.Env represents the ideal form of the VSV vaccine vector.

It is important for future studies to investigate cellular and viral proteins involved in the trafficking
itinerary of the HIV-1 Env protein for future application in rational vaccine designs. As both HIV
Nef and Env share commonalities, such as their use of the adaptor protein complex proteins and
involvement in viral assembly, HIV Nef may play a role in the regulated trafficking of Env to sites
of viral assembly46,47,54. Further investigation into Nef’s potential involvement may elucidate key
cellular interacting partners or domains of Env for inclusion in future vaccine Env immunogens.

1.5 Hypothesis and specific aims
The overall objectives of this project were: (1) to generate and characterize novel chimeric HIV-1
Env proteins for enhanced expression on and immunogenicity of the VSV vaccine platform
(particularly bNAbs), (2) to enhance the tropism of the VSV-Env vector beyond CD4+CCR5+
cells by including full-length EBOV GP in cis and, (3) to elucidate the potential role of HIV-1 Nef
in HIV Env trafficking. Our investigation can be used in the design of novel HIV vaccine in the
future. I hypothesized that replacing the transmembrane and cytoplasmic tail regions of HIV-1 Env
with that of SIVmac239 Env or EBOV GP and utilizing HIV-1 A74 EnvK425 would allow for
enhanced expression and immunogenicity of Env on the VSV vector. I also hypothesized that coexpressing EBOV GP alongside a chimeric HIV-1 Env from the VSV vector would enhance vector
immunogenicity in mice due to enhanced replication of the vector. Lastly, given the commonality
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of cellular adaptor protein usage and subcellular localization of Env and Nef, I hypothesized that
Nef regulates HIV-1 Env trafficking to the plasma membrane.
With this thesis, my aims were to:
1. Determine the effect of co-expressing EBOV GP from the VSV vaccine platform alongside a
chimeric HIV-1 Env protein
2. Develop and characterize chimeric HIV-1 Env immunogens containing the transmembrane and
cytoplasmic tail of SIVmac239 Env and EBOV GP
3. Characterize the immunogenicity of HIV-1 Env chimera generated utilizing HIV-1 A74
EnvK425
4. Determine if wildtype HIV-1 Nef and Env interact and determine the subcellular localization
of said interaction
Overall, the goal of this research is to optimize both the VSV vector and an HIV-1 Env immunogen
for use in the VSV vaccine platform and investigate the involvement of HIV-1 Nef in the complex
trafficking itinerary of HIV-1 Env.
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Chapter 2

2

Materials and Methods

2.1

Cell lines

HEK-293T, CD4+ HeLa, Vero E6 cells (ATCC, Manassas, VA) and TZM-bl cells (NIH AIDS
Reagent Program, Cat. # 8129) were maintained in Dulbecco’s Modified Eagle Medium
(DMEM, Wisent, Quebec, ON) supplemented with 10% fetal bovine serum (FBS, Wisent) and
100 µg/mL of Penicillin-Streptomycin (ThermoFisher Scientific, Waltham, MA). All cells were
grown at 37°C in the presence of 5% CO2 and cultured according to suppliers’ recommendations.

2.2

Plasmids

A summary of the plasmids used in this study and their sources can be found in Table 1. NL4-3
env was subcloned into both a pN1-VN-Flag plasmid encoding the N-terminal portion of the split
Venus fluorophore (VN 1-173) with a Flag-tag and a pN1-eGFP backbone (Clontech) by using
XhoI and BshTI restriction digest enzymes and T4 Ligase (New England BioLabs). NL4-3 Env
and the fluorescent tag were separated with a sequence that encodes a 5 amino acid long linker
region (LVPAT). This linker sequence was generated as a result of the restriction sites utilized for
cloning.
The NL4-3 rev, vpu, and env genes were PCR amplified as a single fragment and cloned into pN1VN-Flag and pN1-eGFP backbones using XhoI and BshTI restriction digest enzymes and the Infusion Cloning kit (TakaraBio). The reverse primer used to amplify NL4-3 rev, vpu, env genes
contained a nucleotide overhang encoding either a 12 amino acids long flexible
(GSAGSAAGSGEF) or rigid (AEAAAKEAAAKA) linker sequence. These linkers were chosen
for testing linker length and properties (i.e. flexibility versus rigidity) are important for maintaining
proper biological function, which often needs to be determined empirically91.
Four expression vectors were produced, termed pN1-Env-F-VN-Flag, pN1-Env-R-VN-Flag, pN1Env-F-eGFP, and pN1-Env-R-eGFP, with “F” and “R” denoting the presence of the flexible or
rigid linker sequence. All primers utilized for cloning are listed in Table 2. Successful cloning of
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all plasmids was confirmed by Sanger sequencing (London Regional Genomics Centre, London,
ON, Canada).
Two VSV-based vaccine constructs (Indiana strain, GenBank: J02428.1) were used in this study,
one expressing the positive-strand RNA complement of the VSV genome with a site for foreign
gene expression (VSVXN2), and one expressing the same VSV genome with the VSV-G gene
replaced with the Zaire Ebola virus glycoprotein gene (pATX-V2-VSVXNΔG/ZEBOVGP)72,92.
The VSVXN2 plasmid contains the five VSV genes (nucleoprotein N, phosphoprotein P, matrix
protein M, glycoprotein G, and polymerase L, respectively), flanked by the bacteriophage T7
promoter, the VSV leader, the hepatitis delta virus ribozyme, and the T7 terminator sequence.
There is a unique MluI/AvrII linker site between the M and G or ZEBOV GP genes, both flanked
by a transcriptional start and stop signal for the expression of an additional gene (Figure 6A).
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Table 1. Summary of plasmids used in this study
Plasmid Name(s)
pNL4-3 F2A-X Nef-eGFP

pN1-KDEL-RFP

pN1-MHC-I-VN
pN1-Nef-VC-V5

pN1-Nef-AxxA-VC
pN1-Nef-E4A-VC
pN1-Nef-DD/GA-VC
pN1-Nef-LL/AA-VC
pN1-Env-VN-Flag
pN1-Env-eGFP
pN1-Env-F-VN-Flag
pN1-Env-R-VN-Flag
pN1-Env-F-eGFP
pN1-Env-R-eGFP-R
pVSVXN2
pATX-V2VSVXNΔG/ZEBOVGP

T7-pCAGGS
pBS-VSV-P
pBS-VSV-N
pBS-VSV-L
pTat

pRSV-Rev

Description
Replication incompetent HIV-1 NL4.3
proviral vector in which a portion of the
gag/pol gene was replaced with the selfcleavage site, F2A, of foot and mouth
disease virus and a multiple cloning
sites (X)
Furthermore, the vector encodes Nef
fused to eGFP48
pN1 red fluorescent protein (RFP)–
KDEL expression vector, encoding RFP
with a prolactin signal peptide sequence
and a KDEL ER retention signal
pN1 vectors encoding fusion proteins of
the N-terminal or C-terminal portions of
the split Venus fluorophore (VN 1-173
or VC 155-273) with MHC-I or NL4-3
Nef, respectively93
pN1 vectors encoding various mutant
forms of HIV NL4-3 Nef fused to the Cterminal portion of the Venus
fluorophore
Mammalian expression vectors
encoding NL4-3 Env or NL4-3 Rev,
Vpu and Env, where Env is fused to
eGFP or VN-Flag tags
Note: “F” and “R” denote the presence
of either a flexible or rigid 12 amino
acid long linker sequence
Modified VSV genomes (with VSV-G
or EBOV GP) with unique cloning sites
for the expression of foreign antigens
under the control of the T7 promotor

Source
Dr. Jimmy
Dikeakos*

VSV helper plasmids required for the
rescue of recombinant VSV particles

Dr. Gary
Kobinger†

Mammalian expression vector encoding
the HIV Tat accessory protein under the
control of CMV promotor
Mammalian expression vector encoding
the HIV Rev accessory protein under the
control of the RSV promotor

Dr. Stephen
Barr*

Dr. David
Heinrichs*

Dr. Jimmy
Dikeakos*

Dr. Jimmy
Dikeakos*

Generated in
this study

Dr. Gary
Kobinger†

Gift from
Didier Trono
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(Addgene
#12253)
pREC.nfl.NL4-3

pNL4-3 Env/SIV Env TMshCT
pNL4-3 Env/EBOV GP TMCT
pA74 Env/SIV Env TMshCT
pA74 Env/EBOV GP TMCT

pCOA74Env/SIV Env TMshCT
pCOA74/EBOV GP TMCT
pCOA74/VSV-G TMCT
pVSVXN2-NL4-3EnvT713
pVSVXN2-NL43Env/SIVTMCT
pATX-V2VSVXNΔG/ZEBOVGP- NL43Env/SIV TMshCT
pATX-V2VSVXNΔG/ZEBOVGP-NL43Env/EBOV TMCT
pATX-V2VSVXNΔG/ZEBOVGPA74Env/SIV TMshCT
pATX-V2VSVXNΔG/ZEBOVGPA74Env/EBOV TMCT
HIV-1 SG3 ΔEnv Non-infectious
Molecular Clone

*Western University, ON, Canada
†
Laval University, QC, Canada

Vector expressing near full-length (nfl)
HIV-1 NL4-3 viral genome lacking the
HIV 5’ LTR94
pcDNA 3.1 (+) vectors encoding HIV
NL4-3 and A74 Env with the HIV Env
transmembrane domain (TM) and
cytoplasmic tail (CT) replaced by either
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TM and CT of the EBOV GP
pcDNA 3.1 (+) vectors encoding
chimeric A74 Env chimera produced
with a human codon bias
VSV vaccine construct encoding VSVG and various chimeric HIV-1 Env
genes

Dr. Eric Arts*

VSVΔG vaccine construct encoding
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gene and containing a defective vpu
gene

NIH AIDS
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# 11051)

Generated in
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using
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Table 2. Oligonucleotide primers used for cloning
Primer Name
NL4-3Env-VN/eGFP-F
NL4-3Env-VN/eGFP-R
RevVpuEnv-VN/eGFP-F
RevVpuEnv-VN-Flex-R
RevVpuEnv-VN-Rig-R
RevVpuEnv-eGFP-Flex-R
RevVpuEnv-eGFP-Rig-R
pcNL4.3-F
pcA74-F
pcSIV-R
pcEb-R

pATX.NL4.3-F
pATX.A74-F
pATX.COA74-F
pATX.T713-R
pATX.SIV-R
pATX.Eb-R
pATX.CO.SIV-R
pATX.CO.Eb-R
pATX.CO.VSV-R

Sequence*
TGCGACCTCGAGATGAGAGTGAAGGAGAAGTATCAGCAC
GATCTAACCGGTAATAGCAAAATCCTTTCCAAGCCCTGTC
GGACTCAGATCTCGAGATGGCAGGAAGAAGCGGAGAC
CACGGTGGCGACCGGGAACTCGCCGCTTCCAGCGGCGCTGC
CGGCGCTGCCTAGCAAAATCCTTTCCAAGCCCTG
CACGGTGGCGACCGGGGCCTTGGCAGCGGCCTCCTTGGCAG
CGGCCTCGGCTAGCAAAATCCTTTCCAAGCCCTG
CATGGTGGCGACCGGGAACTCGCCGCTTCCAGCGGCGCTGC
CGGCGCTGCCTAGCAAAATCCTTTCCAAGCCCTG
CATGGTGGCGACCGGGGCCTTGGCAGCGGCCTCCTTGGCAG
CGGCCTCGGCTAGCAAAATCCTTTCCAAGCCCTG
TTAAACTTAAGCTTGCCACCATGAGAGTGAAGGAGAAGTAT
CAGC
TTAAACTTAAGCTTGCCACCATGAGAGTGAAGGAGATACAG
AGG
AAACGGGCCCTCTAGCTAGAGCAACTTAGCCAGCATCTG
AAACGGGCCCTCTAGCTAGAAGACGAACTTGCAGATACAG
CGATCTGTTTACGCGTATGAGAGTGAAGGAGAAGTATCAGC
TCGATCTGTTTACGCGTATGAGAGTGAAGGAGATACAGA
CGATCTGTTTACGCGTATGAAGTTCCTGGTGAACGTGGC
GAGTTACTTTCCTAGGCTGCCTAACTCTATTCACTATAGAAA
GTAC
AGTTACTTTCCTAGGCTAGAGCAACTTAGCCAGCATCTG
AGTTACTTTCCTAGGCTAGAAGACGAACTTGCAGATACAGA
AC

GAGTTACTTTCCTAGGCTACAGCAGCTTGGCCAGC
GAGTTACTTTCCTAGGCTAAAACACGAACTTACAGATGCA
GAGTTACTTTCCTAGGCTACTTGCCCAGGCGGTTCATCTCG
*All primers are listed in 5’ to 3’ orientation
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2.3

Transfections

Unless otherwise stated, plasmid transfections were performed using polyethylenimine (Sigma
Aldrich, St. Louis, MO) according to manufacturer’s instructions. For western blot analysis of Env
expression in HEK-293T cells, a total of 4 µg of DNA, 3 µg Env expression vector and 1 µg HIV
Rev or empty vector, was transfected. For Bimolecular fluorescence complementation (BiFC) and
co-localization studies, 3.0×104 HeLa cells were seeded onto coverslips and 24 hours later
plasmids were transfected into cells at equal molar ratios, with a total of 800 ng of DNA, using
PolyJet transfection reagent (FroggaBio, Toronto, Canada). For rVSV rescue experiments,
Lipofectamine 2000 was used according to manufacturer’s instructions (TheroFisher Scientific),
and the amount of DNA transfected is outlined in section 2.5.

2.4 Construction of chimeric HIV-1 Env proteins
To produce alternative HIV-1 env genes optimized for expression in VSV, the transmembrane and
cytoplasmic tail domains (TM + CT) of HIV env were replaced with a TM + CT mutant of
SIVmac239 env (GenBank: AAV65325.1) or the TM + CT of the Zaire EBOV GP (GenBank:
AAB81004.1). The HIV-1 Env chimeras were produced using either HIV-1 NL4-3 env (GenBank:
AFN70961.1) or the hybrid HIV-1 A74(gp120)/NL4-3(gp41) env, which has been previously
described95. Specifically, NL4-3 or A74/NL4-3 env, up to and including the membrane proximal
external region (MPER), were PCR amplified with reverse primers encoding the TM and truncated
CT of SIVmac239 env (Env/SIV TMshCT) or TM + CT of EBOV GP (Env/EBOV TMCT) and
subsequently cloned into the unique cloning site of pATX-V2-VSVXNΔG/ZEBOVGP. The HIV
Env/SIV TMshCT mutant was shown to have increased cell surface expression and was produced
by the lab of Dr. Xiaojian Yao, University of Manitoba, who is a collaborator of the VSV-based
HIV vaccine project (unpublished data). The chimeric NL4-3/SIV-TMCT gene was also cloned
into the unique cloning site of VSVXN2. In addition to the above Env chimera, a truncated form
of NL4-3 Env was produced which has been shown to enhance surface levels of HIV-1 Env27. The
NL4-3 Env cytoplasmic tail was truncated at amino acid position 713, termed NL4-3T713, and
cloned into the VSVXN2 construct. Relevant TM + CT sequences and the generation of new HIV1 env genes is depicted in Figure 6B-D.
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Three additional chimeric HIV-1 env genes were produced based on the hybrid HIV-1 A74/NL43 env gene. To enhance the surface expression of HIV-1 Env, the Env signal sequence was replaced
with the signal sequence of honeybee melittin, as shown in Figure 6E84. The HIV A74/NL4-3 TM
+ CT sequence was replaced with a mutant TM + CT of SIVmac239 Env, or the TM + CT of Zaire
EBOV GP, or VSV-G (GenBank: M11048.1). The synthetic coding sequences were then altered
to have a mammalian codon usage bias and to remove any negative cis regulatory elements, using
the gene optimization service from GenScript. These three HIV-1 Env chimeras, referred to as
codon optimized A74 (COA74) Env chimeras, were synthesized and cloned into the pcDNA3.1
expression vectors by GenScript and later cloned into the pATX-V2-VSVXNΔG/ZEBOVGP
vaccine construct by In-Fusion cloning. All chimeric HIV-1 genes generated are listed in Table 3.
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Figure 6. Schematic of VSV vaccine constructs and chimeric HIV-1 Env mutants. (A) VSV
vaccine constructs, containing either VSV-G or the Zaire Ebola virus glycoprotein (EBOV GP).
(B) A depiction of the HIV-1 Env regions. SP: signal peptide. RRE: rev response element. MPER:
membrane proximal external region. TM: transmembrane domain. CT: cytoplasmic tail domain.
(C) Partial amino acid sequences of HIV-1 NL4-3 Env, SIVmac239 Env, EBOV GP, and VSV-G
are shown, including a portion of the MPER, TM and CT domains. (D) Illustration of the HIV-1
Env TM + CT mutants created for expression studies. The TM + CT domains of each virus
(SIVmac239 Env TM + CT mutant) replaced the HIV-1 Env TM + CT. A truncated form of HIV1 Env (EnvT713) and the HIV-1 Env/SIV-TM+CT variant are depicted. The CT of SIVmac239
Env was truncated leaving 3 amino acids, with the third being mutated from R→L (mutant residue
shown in red). (E) The HIV-1 A74 Env and honeybee melittin signal peptides are shown with the
predicted signal peptide cleavage site depicted with a red arrow. The HIV-1 A74 signal peptide up
to the site of cleavage was replaced with melittin signal peptide. “*”: stop codon. “. . .”:
continuation of sequence.
Table 3. HIV-1 Env immunogens generated and their respective destination vectors
Signal
PeptideA
WT

HIV-1 Envelope
NL4-3

WT

NL4-3

TM and CT SourceB
NL4-3 Truncated
(T713)

Destination Vectors
pVSVXN2
pATX-V2-VSVXNΔG/ZEBOVGP

SIV Env truncated
pVSVXN2
(TMshCT)
pATX-V2-VSVXNΔG/ZEBOVGP
WT
NL4-3
EBOV GP TMCT
pATX-V2-VSVXNΔG/ZEBOVGP
WT
A74/NL4-3 hybrid
SIV Env truncated
pATX-V2-VSVXNΔG/ZEBOVGP
(TMshCT)
WT
CO.A74/NL4-3 hybrid SIV Env truncated
pATX-V2-VSVXNΔG/ZEBOVGP
(TMshCT)
Hb
CO.A74/NL4-3 hybrid SIV Env truncated
pATX-V2-VSVXNΔG/ZEBOVGP
(TMshCT)
WT
A74/NL4-3 hybrid
EBOV GP TMCT
pATX-V2-VSVXNΔG/ZEBOVGP
WT
CO.A74/NL4-3 hybrid EBOV GP TMCT
pATX-V2-VSVXNΔG/ZEBOVGP
Hb
CO.A74/NL4-3 hybrid EBOV GP TMCT
pATX-V2-VSVXNΔG/ZEBOVGP
Hb
CO.A74/NL4-3 hybrid VSV-G TMCT
pATX-V2-VSVXNΔG/ZEBOVGP
A
wild-type (WT) refers to the natural signal peptide of the respective HIV-1 Env.
B
TM and CT: Transmembrane and Cytoplasmic tail.
Hb, honeybee melittin; CO, codon optimized; shCT, shortened cytoplasmic tail; T713, NL4-3
CT truncated at amino acid position 713.
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2.5 Recombinant VSV rescue
For the rescue of recombinant VSV particles, 1.5×105 HEK-293T and Vero E6 cells were plated
together in each well of a 6-well plate. At 70% confluency, the cells were transfected with the
VSV helper plasmids which encode the viral ribonucleoprotein constituents (2 µg T7-pCAGGS,
1.25 µg pBS-VSV-P, 0.5 µg pBS-VSV-N, and 0.25 µg pBS-VSV-L) and 2 µg of the plasmid
encoding a recombinant VSV genome described above. Transfections were performed with
Lipofectamine 2000 (ThermoFisher Scientific) according to manufacturer’s instructions.
Recovery of rVSV particles was confirmed by monitoring for cytopathic effects (~4-6 days) at
which point supernatants were collected and analyzed for chimeric Env expression by Western
blot.

2.6

Western blots

For analysis of total cellular expression of chimeric HIV-1 Env proteins and the fluorescently
tagged NL4-3 Env proteins, HEK-293T cells were transfected with the Env expression vectors,
washed once with 1X phosphate buffered saline (PBS) 24 hours later and lysed in lysis buffer (0.5
M HEPES, 1.25 M NaCl, 1 M MgCl2, 0.25 M EDTA, 0.1% Triton X-100, 1X complete protease
inhibitor; Roche, Indianapolis, IN). Cells were placed on a rotator for 20 minutes at 4°C before
scrapping and removing insoluble cellular debris by centrifugation at 20,000  g for 20 minutes.
Cell lysates were boiled at 93°C in 5X SDS-PAGE sample buffer (0.312 M Tris pH 6.8, 25% 2Mercaptoethanol, 50% glycerol, 10% SDS) for 15 minutes and store at -20 °C. Proteins were
separated via 8% SDS-PAGE gel and subsequently transferred to nitrocellulose membranes.
Membranes were stained with ponceau dye, washed 3 times for five minutes each with TBST then
blocked in 5% non-fat skimmed milk (BioShop Canada, Burlington, Canada) in 1X TBST
containing 0.1% Triton X-100 for 1 hour at RT, then incubated overnight at 4°C with various
primary antibodies: clarified hybridoma supernatant containing mouse anti-gp120 (B13)
monoclonal IgG (provided by George Lewis, Institute of Human Virology, Baltimore, MD, and
Bruce Chesebro, NIAID, Hamilton, MT), rat anti-DYKDDDK (anti-Flag) monoclonal IgG
(1:5000; BioLegend), rabbit anti-GFP polyclonal Ab (1:5000; Takara Bio Clontech), and anti-actin
mAb (1:3000; ThermoFisher Scientific). Membranes were then washed with 1X TBST and
incubated for 1.5 hours with the appropriate species-specific HRP-conjugated secondary
antibodies (1:3000 for anti-Env and anti-actin, 1:5000 for anti-Flag and anti-GFP; Thermo
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Scientific). All blots were developed and quantified using ECL substrates (Millipore Inc.,
Billerica, MA) and either a Gel Doc EZ Imager (Bio-Rad) or C-DiGit chemiluminescence Western
blot scanner (LI-COR Biosciences).
For the analysis of rVSV particle protein content, 106 plaque forming units (PFU) of rVSV
particles were mixed with 5X SDS-PAGE sample buffer and boiled for 15 minutes at 93°C.
Subsequently, the proteins were separated via 8% SDS-PAGE gel and transferred to nitrocellulose
membranes. Membranes were blocked in 1% bovine serum albumin (BSA) (in TBST containing
0.1% Triton X-100) for 1 hour at RT, then incubated overnight at 4°C with various antibodies:
mouse anti-gp120 (B13) mAb, mouse anti-VSV-N (10G4) mAb (1:1000; Kerafast), mouse antiZaire Ebola virus glycoprotein (4F3) mAb (1:1000; IBT Bioservices) , and rabbit anti-VSV-G
(1:1000; Abcam). Membranes were then washed in 1X TBST and incubated for 1.5 hours with the
appropriate species-specific HRP-conjugated antibodies (1:1000 for all; Thermo Scientific). All
blots were developed and quantified using ECL substrates (Millipore Inc., Billerica, MA) and a
Gel Doc EZ Imager (Bio-Rad).

2.7

rVSV immunogenicity study

Seven 6-8 week old female BALB/c mice per test group (5 groups) received an intraperitoneal (IP)
inoculation with 20 µL PBS containing 106 PFU of rVSV particles. The five groups received
immunizations with the following rVSV: rVSV-EBOV, VSVG-NL4-3T713, VSVΔG-EBOVNL4-3T713,

VSVG-NL4-3/SIV

TMshCT,

and

VSVΔG-EBOV-NL4-3/SIV

TMshCT,

respectively. At day twenty-eight, blood was collected via cardiac puncture and serum was
isolated. All experiments were monitored and performed in compliance with the Laval University
Council on Animal Care.
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2.8 Detection of anti-HIV Env Abs using enzyme-linked
immunosorbent assay (ELISA)
ELISA was used to assess serum anti-HIV Env antibody titers. Plates were coated with 100ng of
D7324 (anti-HIV-1 Env gp120 C5) in 50 uL PBS and incubated at 4°C overnight74. The plates
were washed 5x with PBS containing 0.05% Tween-20, and subsequently blocked with 5% BSA
in PBS for 1 hour at 37°C. 50 ng of purified JR-FL gp140 trimer protein was subsequently added
to each well and incubated for 1 hour at 37°C, followed by 5 washes. Sample dilutions were
prepared using blocking buffer and were applied at 50uL per well in duplicates. Samples were
incubated at 37°C for 1 hour. Unbound antibodies were removed by washing with wash buffer.
Next, 50 μL of HRP-conjugated goat anti-mouse IgG secondary Ab (1 µg/mL) was used for the
detection of anti-HIV Env IgG Abs. Assay was developed using 50 μL/well of SureBlue TMB 1component microwell peroxidase substrate (SeraCare) and stopped after 5 minutes with 50 μL of
0.1 N H2SO4. Optical densities (OD) were measured using the Cytation5 imaging reader (BioTek)
at 450 nm using Gen5 software.

2.9 Analysis of Env nucleotide sequences using GenScript rare codon
analysis tool
To investigate the suitability of the NL4-3 and A74 coding sequences for expression in a human
system, the GenScript rare codon analysis tool was utilized. The nucleotide sequences of NL4-3
(GenBank: AFN70961.1) and A74 Env (GenBank: JX993970.1) were inputted into the analysis
tool, host expression system was set to “human”, and the analysis was run. Analysis report
provided the codon adaptation index (CAI) value, which represents how well a specific gene will
be expressed in a particular host organism. CAI values can range from 0.0-1.0, with a value within
0.8-1.0 considered ideal. In addition to the CAI value, the number of negative cis regulatory
elements (CRE), which refer to sequence motifs that negatively regulate the gene expression at the
transcription or translation level, were reported. The GenScript rare codon analysis tool was
accessed at https://www.genscript.com/tools/rare-codon-analysis.

2.10 Immunofluorescence
For subcellular localization and BiFC studies, CD4+ HeLa cells plated on glass coverslips in 12well plates were transfected with equal molar ratios of plasmids, with 800 ng of DNA using the
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cationic lipid transfection reagent PolyJet following recommended manufacturer’s instructions.
HeLa cells used in the BiFC studies were incubated in the absence of light at RT for 2 hours prior
to fixation to allow the fluorophores to mature. Cells were washed twice with 1X PBS, fixed for
15 minutes in 4% paraformaldehyde and subsequently washed three times in 1X PBS. To stain for
the proteins of interest and various intracellular compartments, cells were incubated in
permeabilization/blocking buffer (5% BSA and 0.1% Triton X-100 in 1X PBS) for 1 hour. Cells
were then incubated with the appropriate antibodies diluted in blocking buffer for 2 hours (Mouse
anti-gp120 B12 (NIH, cat # 2640), 1:200; Rabbit anti-TGN46 (Sigma Aldrich), 1:100; Rat antiFlag (Biolegend), 1:400; Rabbit anti-V5 (Sigma Aldrich), 1:400). Cells were subsequently washed
three times for five minutes each in blocking buffer and incubated with the appropriate secondary
antibody diluted in blocking buffer (donkey anti-mouse AlexaFluor 647/Cy3, donkey anti-rabbit
Cy3, donkey anti-Rat AlexaFluor 647 (1:400; Jackson ImmunoResearch)) for 2 hours at RT.
Finally, cells were washed three times for five minutes each in 1X PBS and mounted onto glass
slides using DAPI-Fluoromount-G (Southern Biotech). Glass slides with mounting solution were
allowed to dry overnight before imaging and storage at 4°C.

Cells were viewed on a Leica DMI6000 B at 63X or 100X magnification using the FITC, Cy3,
Cy5, and DAPI filter settings and imaged with a Photometrics Evolve 512 Delta EM-CCD camera.
Images were subsequently deconvolved using the Advanced Fluorescence Deconvolution
application on the Leica Application Suite software (Lecia, Wetzlar, Germany). Co-localization
analysis was conducted using Pearson’s Correlation from the ImageJ plugin JACoP, as described
previously96.

2.11 Flow cytometry
To test the cell surface expression of chimeric Env proteins, HeLa cells were transfected with the
various chimeric Env expression vectors as described above. Twenty-four hours posttransfection, cells were trypsinized, washed twice with 1X PBS and fixed in 1.5% PFA for 15
minutes. Following fixation, cells were washed in cell staining buffer (Biolegend) and stained
with anti-HIV-1 gp120 monoclonal IgG (NIH Cat # 2640, B12, 1:400) antibody for 1 hour. Cells
were then washed twice and stained with donkey anti-mouse AlexaFluor 647 (1:400) for one
hour, followed by two washes in cell staining buffer. Flow cytometry was then performed using
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a BD FACSCanto (BD Biosciences) and the geometric mean fluorescence intensity of
AlexaFluor 647 (Env) was determined for live singlet HeLa cells.

2.12 Cell-cell fusion assay
To test the functionality of the chimeric HIV-1 Env proteins and the fluorescently tagged NL4.3
Env proteins, HeLa cells were co-transfected with the various Env expression plasmids and pTat.
pREC.nfl.NL4-3 and pTat were transfected as positive and negative controls, respectively.
Twenty-four hours post-transfection, HeLa cells were lifted with 6.25 mM EDTA, and washed
with complete DMEM. Additionally, TZM-bl cells were lifted and washed and 1.0×105 cells of
both cell types were added together in a well of a 96 well plate. Cells were then centrifuged at 400
× g for 30 seconds to aid in cell adhesion. Twenty-four hours later, cell-cell fusion was analyzed
using the Galacto-star assay kit (ThermoFisher Scientific). Briefly, media was removed, and cells
were lysed for 10 minutes in Galacto-star lysis solution with agitation at 600 rpm. Cell debris was
pelleted at 1700 × g for 5 minutes and 10 µL of supernatant was transferred to a new white solid
bottom 96 well plate. After the addition of 100 µL of Galacto-star reaction buffer and incubation
at RT for 50 minutes, light emission was measured with BioTek Cytation 5 Imaging reader using
the standard luminescence protocol on the Gen5 software (BioTek Instruments, Inc. Winooski,
VT). In certain instances, Env-mediated cell-cell fusion was inhibited with the addition of HIV
entry inhibitors, maraviroc (MVC; 40 µM) or T-20 (10 µM), added at the time of HeLa and TZMbl cell combination. Stock solutions of MVC were diluted in PBS and filter sterilized. Stock
solutions of T-20 were diluted in ethanol. T-20 was obtained from the AIDS Research and
Reference Reagent Program.

2.13 Pseudovirus infectivity assay
To test the functionality of chimeric A74 Env proteins and the NL4-3-F/R-VN-Flag and -eGFP
fusion proteins, HIV pseudoviruses were produced by co-transfecting HEK-293T cells with Env
expression vectors and the S3G-ΔEnv plasmid at a 1:3 ratio (1 µg:3 µg for a 10 cm dish). After 48
hours, pseudovirus-containing supernatants were collected, filtered through a 0.45 µm filter, and
added to wells of a 96-well plate containing 2.0×104 TZM-bl cells in serial 2-fold dilutions. Cells
and pseudovirus supernatants were incubated for 48 hours at 37°C to allow for infection and
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expression of β-Galactosidase. Virus infectivity was analyzed using the Galacto-star assay kit as
described above.

2.14 Statistical analyses
GraphPad Prism v6.01 was used for all statistical analyses. P values and statistical tests were stated
where appropriate. P values less than 0.05 were deemed significant.
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Chapter 3

3

Results

3.1 Construction of chimeric HIV-1 Env proteins for enhanced
immunogenicity and expression on VSV-HIV vaccine particles
In order to improve upon the IAVI VSV-HIV vaccine, VSVΔG-Env.BG50580, multiple avenues
were pursued. First, we aimed to generate novel Env chimera with enhanced incorporation into
rVSV particles by replacing the Env transmembrane (TM) and cytoplasmic tail (CT) domains with
those of SIV Env and EBOV GP. SIV Env, especially with a truncated CT, has enhanced cell
surface levels, which may translate to enhanced incorporation into rVSV particles27,82. Similarly,
EBOV GP is able to easily pseudotype VSV particles, thus, Env chimera expressing the EBOV
GP TMCT may also be incorporated into rVSV particles at high levels (REF). As a second avenue
for improving the IAVI VSV-HIV vaccine, we also aimed to enhance Env chimera
immunogenicity by utilizing a strain of HIV-1 Env referred to as A74. HIV-1 A74 Env is believed
to assume a more open conformation revealing epitopes that may aid in the elicitation of
bNAbs43,75. As a control for expression and immunogenicity, Env chimera were also produced
with a lab-adapted strain of HIV-1 Env, NL4-3. Therefore, chimeric NL4-3 and A74 Env
immunogens were created containing the TM and CT of EBOV GP and the TM and
truncated/shortened CT of SIV Env, as shown in Figure 7B. In addition to these Env chimera, we
also generated a truncated form of NL4-3 Env by removing the majority of the CT, referred to as
NL4-3EnvT713, as this Env has been shown to have enhanced cell surface expression (REF). The
third major avenue pursued for improving the IAVI vaccine was abolishing its reliance on
CD4+/CCR5+ cells for replication, a potentially detrimental characteristic of the IAVI vaccine, by
including the VSV-G or EBOV GP gene in the VSV vector. VSV-G and EBOV GP both have
broad cellular tropisms as they use widely expressed entry receptors, thus, their inclusion may also
enhance rVSV replication in vivo to potentially enhance immunogenicity88,97. Altogether, the
various Env chimera described above were cloned into the pcDNA3.1 expression vector, VSVG,
and VSVΔG-EBOV GP vaccine vectors for characterization (Figure 7C). Initial studies to
determine the optimal VSV vaccine vector (VSVG or VSVΔG-EBOVGP) utilized the chimeric
HIV-1 NL4-3T713 and NL4-3/SIV TMshCT genes. All HIV-1 Env chimera described are depicted
in Figure 7, and a more detailed description of their construction is shown in Figure 6.
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B

C

Figure 7. Cloning and testing of new HIV-1 Env chimeras for enhanced expression on
VSVΔG particles. (A) Wildtype (WT) HIV Env is made up of two main subunits, gp120 and
gp41. Gp120 contains the Env signal peptide (SP) and rev-response element (RRE). Gp41 contains
the extracellular domain (ECD), transmembrane domain (TM), and cytoplasmic tail (CT). (B)
Various Env chimera were generated based on HIV-1 NL4.3 and A74 Env by replacing the HIV
Env TMCT with the TM and truncated (sh) CT of SIV Env (green) or Ebola glycoprotein (black).
A truncated form of NL4.3 Env was also generated by truncating the Env CT at amino acid 713
(HIV Env.NL4.3T713). (C) The various Env chimeras were cloned into both pcDNA3.1 and VSV
vaccine vectors via In-fusion cloning and their expression and functional characteristics were
investigated. The VSV vaccine vector contains all the VSV protein coding sequences (VSV-N, P, -M, and -L) with either the VSV (VSV-G) or Ebola glycoprotein (EBOV GP) genes located
before the VSV-L protein coding region.
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3.2 Ebola virus glycoprotein enhances anti-Env antibody responses in
mice
A potential limitation of the VSVΔG-Env.BG505 vaccine is that it solely relies on CD4+/CCR5+
cells for in vivo replication, which may have provided the high degree of protection seen in
macaque pre-clinical trials by depleting these cells75. As an alternative approach, inclusion of
VSV-G or EBOV GP into the VSV vaccine platform, which both have broad cellular tropisms,
may abolish the need for CD4+/CCR5+ cells for replication88,97. Therefore, we aimed to test the
effects of co-expressing VSV-G or EBOV GP alongside chimeric HIV-1 Env from the VSV
vaccine vector on the incorporation levels of chimeric HIV-1 Env protein and the immunogenicity
of the vaccine particles. Recombinant VSV (rVSV) particles expressing the truncated NL4-3 Env
mutant or NL4-3 Env/SIV Env TMshCT chimeric proteins and either VSV-G or EBOV GP were
generated, and after purification were lysed and analyzed by western blot for protein content.
Specifically, levels of Env, VSV-G, and EBOV GP were investigated, with protein content
normalized based on the VSV-N structural protein which migrates at ~48 kDa (Figure 8A).
Quantification revealed that the NL4-3 Env/SIV Env TMshCT chimeric protein was incorporated
into rVSV particles to a greater extent than the truncated NL4-3 Env mutant (NL4-3T713), whether
VSV-G or EBOV GP was present. Additionally, the incorporation of NL4-3T713 and NL4-3/SIVTMshCT were both greater in the presence of VSV-G versus EBOV GP (Figure 8A).

Next, the immunogenicity of these NL4-3T713 and NL4-3/SIV-TMshCT rVSV particles
containing VSV-G or EBOV GP were tested by immunizing BALB/c mice (N=7 per group) with
106 plaque forming units (PFU) of each rVSV. Four weeks post-immunization, mouse serum was
collected and analyzed for anti-HIV Env IgG by ELISA. Analysis revealed that co-expression of
EBOV GP in rVSV particles enhanced anti-Env Ab responses against the NL4-3T713 Env
(p<0.05, student’s t-test) but not the NL4-3/SIV chimeric Env (p>0.05, student’s t-test) when
compared to VSV-G co-expression (N=7 per group). Overall, these results support the inclusion
of EBOV GP within the VSV vaccine vector.
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A

B

Figure 8. Enhanced immunogenicity of rVSV particles co-expressing EBOV GP and HIV NL4-3
Env/SIV TMshCT. (A) Rescued rVSV particles were lysed and analyzed by western blot for
chimeric Env (gp140/gp120), VSV-G, EBOV GP (GP1), and VSV-N content. Densitometric
analysis of western blots, with VSV-N used as a loading control (N=1). (B) BALB/c mice (N=7
per group) were immunized with 106 PFU of each rVSV and four weeks post-immunization blood
was drawn, purified, and analyzed for an anti-Env IgG response by ELISA. * P<0.05. Student’s ttest. Error bars represent standard error of mean (SEM).
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3.3 Incorporation levels of NL4-3 Env chimera greatly surpass that of
A74 Env chimera in rVSV particles
As proof of concept, our initial experiments utilized NL4-3-based Env chimera, derived from a
lab-adapted strain of HIV-1, for determining the ideal VSV vaccine construct. However, in order
to generate a robust humoral response upon vaccination, we aimed to generate Env chimera based
on HIV-1 A74 Env. A74 Env, characterized by the Arts laboratory, is believed to prefer a more
open conformation that may help to elicit that production of anti-Env bNAbs75,95. Accordingly,
recombinant VSVΔG-EBOV particles expressing NL4-3- and A74-based Env chimera with either
SIV Env TMshCT or EBOV GP TMCT were produced. Recombinant VSV particles were lysed
and analyzed by western blot for the incorporation levels of chimeric Env proteins. Unexpectedly,
analysis of rVSV particles showed that NL4-3 Env chimera were incorporated into VSV particles
at much greater levels than that of A74 Env chimera (Figure 9A). Interestingly, incorporation of
the chimeric A74/EBOV protein was undetectable. These results suggest that the A74 Env gp120
sequence, which is the only difference between Env chimera generated based on NL4-3 or
A74(gp120)/NL4-3(gp41), is the reason for lower incorporation into the rVSVΔG-EBOV GP
particles.

Despite having identical sequences, except for their gp120 regions, the NL4-3 and A74 Env
chimera proteins had drastically different levels of incorporation into rVSVΔG-EBOV GP
particles. The presence of negative cis-regulatory elements (CRE) or a suboptimal codon usage
bias for expression in an organism of interest could negatively affect transcription or translation,
respectively. To determine if low incorporation levels of chimeric A74 proteins is a result of the
A74 Env gp120 nucleotide sequence, we analyzed the gp120 nucleotide sequences of NL4-3 and
A74 Env using the GenScript rare codon analysis tool98. Analysis revealed that the NL4-3 and A74
gp120 nucleotide sequences had similar codon adaptation index (CAI) values for expression in a
mammalian host, 0.69 and 0.67, respectively (Figure 9B). Interestingly, A74 gp120 contained
three times as many CREs than NL4-3 gp120 (nine versus three), suggesting the A74 gp120 coding
sequence may be less suited for expression in a mammalian system.
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Figure 9. Incorporation levels of NL4.3 Env chimera greatly surpass that of A74 Env chimera
in rVSV particles. (A) Recombinant VSV particles were lysed and analyzed by Western blot for
chimeric Env (gp140/gp120), and VSV-N content. (N=1). VSV-N was used as a loading control.
(B) The nucleotide sequences of NL4.3 and A74 gp120 were analyzed using the GenScript rare
codon analysis tool to determine their overall suitability for expression in a mammalian system
(Codon Adaptation index for expression in a mammalian system) and number of negative cisregulatory elements (CRE). Codon Adaptation index ranges from 0.0-1.0, with values of 0.8-1.0
often giving high expression in the desired organism.
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3.4 Codon-optimization and honeybee melittin signal peptide greatly
enhance expression of chimeric A74 Env proteins
An effective vaccine not only requires an optimal immunogen but also sufficient levels of that
immunogen to generate a protective immune response. To enhance the incorporation of A74 Envbased chimeric HIV proteins into rVSVΔG-EBOV GP particles, we aimed to enhance their total
and cell surface expression levels by codon optimizing the A74 Env coding sequence and replacing
the HIV-1 Env signal peptide. First, the HIV-1 Env signal peptide, which is known to significantly
slow down Env synthesis, was replaced with the signal peptide of the honeybee melittin (Hb-SP)
protein, which has been previously shown to enhance HIV-1 Env expression84. Second, we
synthesized the A74 Env chimera with a human codon bias to both optimize expression in
mammalian cells and destroy negative cis regulatory elements99. Therefore, we generated three
codon optimized (CO), Hb-SP containing A74 Env chimera with either the SIV Env TMshCT,
EBOV GP TMCT, or the VSV-G TMCT. Additionally, a fourth CO, Hb-SP A74 Env chimera
containing the VSV-G TMCT was produced with the rev-response element nucleotide sequence
kept intact. . These codon optimized HIV-1 chimeras, referred to as COA74 HIV Env chimeras,
were synthesized by GenScript and cloned into both pcDNA3.1 vectors and the VSVΔGEBOV
vaccine construct (Figure 10A).

To investigate the effect of the Hb-SP and mammalian codon bias on total expression of the A74
Env chimeras, HEK-293T cells were transfected with pcDNA3.1 encoding chimeric NL4-3, A74,
and COA74 Env proteins. Due to the presence of HIV-1 mRNA splice sites and therefore
dependence on Rev for proper expression, the NL4-3 and A74, but not COA74 Env constructs,
were also co-transfected with an HIV-1 Rev encoding plasmid. Western blot analysis of cell lysates
revealed that all COA74 Env chimeras were expressed significantly higher than the NL4-3 and
A74 Env chimeras (Figure 10B, C). The COA74 Env proteins containing SIV TMshCT or VSVG TMCT were expressed significantly higher than the chimeric HIV-1 Env COA74-EBOV GP
TMCT protein. Western blot analyses confirmed that the COA74 constructs, even with the RRE
intact, were Rev-independent (Supplementary Figure 1).
The incorporation of glycoproteins into budding VSV particles occurs at the plasma membrane100.
Therefore, we next investigated the cell surface levels of COA74 Env chimeras. HeLa cells were
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transfected with pcDNA3.1 expression vectors encoding the NL4-3, A74, and COA74 Env
chimeras, depicted in Figures 7B and 10A, and Env expression was analyzed via flow cytometry.
HeLa cells were gated for live, single cells and Env expression and the mean fluorescence intensity
was quantified (Figure 10D, E). Preliminary results revealed that the mean fluorescence intensities
of COA74 Env chimera were much greater than NL4-3 and A74 Env chimera. Altogether, these
results suggest that the addition of the Hb-SP and codon optimization greatly enhanced both total
and cell surface expression of the COA74 Env chimera over the non-codon optimized NL4-3 and
A74 Env chimeras.
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Figure 10. Codon-optimization and honeybee melittin signal peptide greatly enhance
expression levels of chimeric A74 Env proteins. (A) New chimeric Env proteins based on HIV1 A74 Env were generated by replacing the wildtype Env signal peptide with that of honeybee
melittin (Hb-SP), replacing the TM+CT of Env with that of SIV Env, EBOV GP, or VSV-G, and
codon optimizing (indicated by crosshatching) the entire gene with a human codon bias. It is
important to note that the rev-response element (RRE) was destroyed by codon optimization. (B)
HEK-293T cells were co-transfected with NL4.3, A74, or codon optimized A74 Env chimera
pcDNA3.1 expression vectors, with or without pRSV-Rev. Twenty-four hours after transfection,
total Env chimera expression levels in cell lysates were analyzed by Western blot using anti-Env
(B13). β-actin was measured as a loading control (N=3) (C) Densitometry analysis of chimeric
Env expression relative to pREC.nfl.NL4-3. Bars carrying different letters are significantly
different (P<0.0001, except “d vs. a” has P<0.01. One way ANOVA followed by Dunnett’s
multiple comparisons test was used to determine statistical significance (N=3). (D) HeLa cells
were transfected with the various Env chimera expression vectors, stained for chimeric Env
expression with human anti-Env (B12) and anti-human Alexa 647 Abs, and analyzed by flow
cytometry. Representative gating strategy is shown. (E) Quantification of mean fluorescence
intensity for Env expression with background staining of untransfected HeLa cells subtracted
(N=1).
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3.5 Codon optimized A74 Env chimera retain fusion functionality
To determine if the chimeric Env constructs we generated retained the ability to mediate cell-cell
fusion or permit pseudovirus entry, various assays utilizing CD4+CCR5+ TZM-bl cells were
conducted. The TZM-bl reporter cell line, which is susceptible to HIV infection, expresses βGalactosidase in the presence of the HIV-1 Tat protein, which can be used to measure relative
infection. However, because our Env chimera are in the context of pcDNA3.1 expression vectors,
which do not encode for HIV-1 Tat, an HIV-1 Tat expression vector was co-transfected into HeLa
cells such that cell-cell fusion could be detected (Figure 11A). First, HeLa cells were co-transfected
with a Tat expression vector and a NL4-3, A74, or COA74 Env expression vector. Twenty-four
hours later, transfected HeLa cells were lifted and co-cultured with TZM-bl cells. To further
confirm whether the cell-cell fusion detected was a result of Env chimera expression the HIV-1
entry inhibitors T20 and maraviroc (MVC) were also added at concentrations of 10 µM and 40
µM, respectively. Twenty-four hours later cells were analyzed for cell-cell fusion using the
Galacto-star kit, measured as relative light units (Figure 11A). As a positive control, the CXCR4tropic pREC.nfl.NL4-3 construct was transfected. The COA74 Env chimera successfully mediated
cell-cell fusion, whereas, the levels of cell-cell fusion from NL4-3 and A74 Env chimera was only
slightly above the lower limit of detection. The addition of T20, an HIV-1 fusion inhibitor,
inhibited fusion of the pREC.nfl.NL4-3 positive control, but unexpectedly had no to little effect
on COA74/SIV-TMshCT cell-cell fusion (Figure 11B). The impact of T20 on COA74/EBOVTMCT and COA74/VSV-TMCT cell-cell fusion was not tested. The addition of the HIV-1 entry
inhibitor maraviroc (MVC), a CCR5 antagonist which prevents entry by CCR5-tropic HIV-1
strains, had no effect on pREC.nfl.NL4-3 cell-cell fusion, as expected. As expected, MVC greatly
diminished fusion mediated by the COA74 Env chimera.

Next, we tested the ability of the COA74 Env chimera to be incorporated into HIV pseudoviruses
and permit entry into target cells. HEK-293T cells were co-transfected with the COA74 Env
expression constructs and the proviral SG3 ΔEnv vector to produce pseudotyped HIV particles.
Pseudovirus containing supernatant was then titrated onto TZM-bl cells and infectivity was
measured as relative light units (Figure 11C). Relative infection decreased as supernatant was
diluted for all pseudoviruses. Relative infection of HIV pseudovirus expressing COA74/SIV
TMshCT was approximately 2.5 times higher than pseudoviruses expressing COA74/EBOV GP
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TMCT or VSV-G TMCT (Figure 11D). VSV-G pseudotyped HIV particles were generated and
titrated onto TZM-bl cells as a positive control. Overall, these results confirm that the COA74 Env
chimera can be efficiently incorporated into HIV pseudovirions and mediate infection of target
cells.
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Figure 11. Chimeric HIV Env proteins retain entry functionality. (A) Schematic of the cellcell fusion assay. 1. HEK-293T cells were co-transfected with pTat and Env chimera expression
vectors, 2. Twenty-four hours post-transfection, HEK-293T cells are co-cultured with TZM-bl
cells, 3. Env expressing HEK-293T cells and CD4, CCR5/CXCR4 expressing TZM-bl cells fuse
and allow HIV Tat to promote the expression of β-Galactosidase inside the TZM-bl nucleus. Cellcell fusion is then detected using the Galacto-star kit (N=1). (B) Cell-cell fusion abilities of the
various Env chimeras were measured as relative light units with the “cells only” background
control subtracted from each value. The HIV-1 entry inhibitors T20 and maraviroc (MVC) were
also added at 10 µM and 40 µM, to further test Env-mediated cell-cell fusion. If column is not
present, then T-20 or MVC was not added (N=1). (C) Schematic of pseudovirus infectivity assay.
I. HEK-293T cells were co-transfected with SG3ΔEnv and Env chimera expression vectors, II. 48
hours post-transfection, pseudovirus-containing supernatant was collected and filtered, III.
Pseudoviruses were titrated onto TZM-bl cells, IV. Pseudoviruses will infect TZM-bl cells
allowing for the expression of HIV Tat, and therefore β-Galactosidase which is detected using the
Galacto-star kit. (D) Relative light emission of HIV pseudovirus infection at various dilutions
measured using the Galacto-star assay. The background value of uninfected TZM-bl cells was
subtracted from each sample.
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3.6 Effect of codon optimization and honeybee melittin signal peptide
on A74 Env incorporation in rVSV particles
We have shown that codon optimization and addition of the honeybee melittin signal peptide
greatly enhances both total and cell surface levels of A74 Env chimera in the context of pcDNA3.1
(Figure 10), but this may or may not translate to enhanced incorporation in rVSV particles.
Additionally, because codon optimization and the Hb-SP were added together in our initial A74
Env chimera it is unclear if both alterations were necessary for enhanced Env expression.
Therefore, we next aimed to investigate the effects of codon optimization, the honeybee melittin
signal peptide or a combination of both on A74 Env expression in the context of the VSVΔGEBOV GP vaccine platform. Recombinant VSVΔG-EBOV GP particles were rescued expressing;
unaltered A74/SIV TMshCT or A74/EBOV TMCT, codon optimized A74/SIV TMshCT or
A74/EBOV TMCT, and codon optimized Hb-SP containing A74/SIV TMshCT or A74/EBOV
TMCT. rVSV particles were lysed and analyzed for chimeric Env expression by western blot
(Figure 12A). Quantification revealed for that codon optimization of A74/SIV TMshCT appeared
necessary and sufficient for enhanced incorporation into rVSV particles. Interestingly, both codon
optimization and addition of the honeybee melittin signal peptide were required for enhancing
incorporation of the A74/EBOV TMCT Env chimera (Figure 12B). Immunogenicity testing of
rVSVΔG-EBOV particles expressing COA74 Env chimera containing wildtype or Hb-SP is
currently underway.
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Figure 12. Effect of codon optimization and honeybee melittin signal peptide on A74 Env
incorporation in rVSV particles. (A) rVSV particles were generated and 106 PFU were lysed
and analyzed by western blot for chimeric Env (gp140 and gp120), EBOV GP (GP1), and VSVN content (N=1). Molecular weight markers located near relevant proteins is shown in kDa. wt,
wildtype; HbSP, honeybee melittin signal peptide. (B) Densitometric analysis of western blots,
with VSV-N used as a loading control (N=1), with expression relative to A74/SIV TMshCT.
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3.7 Wildtype HIV-1 Env and Nef colocalize within the trans-Golgi
network
Understanding the role of key partners in HIV-1 Env trafficking may reveal important information
which can be utilized for future rational design of a VSV-HIV vaccine. The HIV-1 Env and Nef
proteins have similar subcellular localization and their main functions rely on similar networks of
cellular adaptor proteins. With many aspects of HIV Env trafficking unknown and the role of Nef
as a master regulator of protein trafficking, it is possible Nef may play a role in Env trafficking.
To first investigate if wildtype HIV-1 Env and Nef co-localize, we utilized immunofluorescent
microscopy. To observe both Env and Nef expression, we utilized the replication incompetent
HIV-1 NL4-3 proviral vector, F2AXNef-GFP. This vector was produced by Dirk et al (2015) by
replacing a portion of the gag/pol gene with the self-cleaving site (F2A) of foot and mouth disease
virus followed by a multiple cloning site (X) to allow for expression of transgenes48. Additionally,
this vector also encodes the HIV Nef protein fused to eGFP. HeLa cells were transfected with the
F2AXNef-GFP construct and twenty-four hours post-transfection HeLa cells were immunostained
for HIV-1 Env48. Immunofluorescence analysis revealed a high degree of co-localization of Env
and Nef (Pearson’s = 0.75), which collected in the paranuclear region, suggesting that Nef may
play a role in Env subcellular trafficking (Figure 13A).

We next sought to identify the paranuclear subcellular compartment in which Env and Nef colocalize. HeLa cells were again transfected with the F2AXNef-GFP plasmid and immunostained
for Env. In addition, the cells were also either co-transfected with a vector expressing KDEL-RFP
to visualize the ER, or immunostained for TGN46 to visualize the TGN. Immunofluorescence
analyses revealed that both Nef and Env colocalized with TGN46 to a higher degree than KDELRFP (Figure 13 B-D). These results suggest that Env and Nef may interact within the TGN.
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Figure 13. Env and Nef colocalize within the trans-Golgi network. (A) Co-localization
experiments were conducted by transfecting HeLa cells with the replication incompetent HIV-1
NL4-3 proviral vector lacking gag/pol and containing Nef-GFP and immunostaining for Env
(N=3), and (B) immunostaining for TGN46 (a marker of the TGN), or (C) co-transfecting KDELRFP, which expresses a fluorescent marker in the ER (N=1). GFP was observed under the FITC
channel, Env was observed under the Alexa 647 channel, and KDEL-RFP/TGN46 were observed
under the Cy3 channel. Env was pseudocoloured in yellow. (D) Co-localization was quantified
using Pearson’s correlation through the JaCoP Plug-in on ImageJ. Error bars were calculated for
Env:Nef-GFP co-localization by quantifying at least 30 cells between 3 independent experiments.
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3.8 Construction and verification of Env-VN-Flag and Env-eGFP fusion
proteins
In order to investigate the potential interaction of the HIV-1 proteins Env and Nef, we aimed to
perform a bimolecular fluorescence complementation (BiFC) assay. As previously described,
BiFC involves the expression of a split Venus fluorophore from two distinct expression plasmids
in the form of fusion proteins, and upon close proximity (within 100 nm) of these fusion proteins
the Venus fluorophore is reconstituted101. Therefore, we first required constructs encoding NL4-3
Nef and Env each fused to one half of the Venus fluorophore. A construct encoding a fusion of
NL4-3 Nef to the carboxy (VC) fragment of the Venus fluorophore and a V5 tag on Nef’s Cterminus (Nef-VC-V5) was previously generated by the Dikeakos lab93. A construct encoding a
fusion of NL4-3 Env to the amino (VN) fragment of the Venus fluorophore and a Flag-tag (EnvVN-Flag) on the C-terminus of Env was generated in this study. In addition to this construct, we
also generated a fusion of NL4-3 Env and eGFP (Env-eGFP) to the Env C-terminus to allow us to
conduct live cell imaging in the future. HEK-293T cells were transfected with constructs encoding
Env-VN-Flag or Env-eGFP with or without HIV Rev. Interestingly, western blot analysis of total
cell Env expression detected only low levels of Env fusion proteins in the presence of HIV Rev.
The band showing anti-Env reactivity appeared at ~180 kDa, consistent with the fusion of gp160
and VN-Flag or eGFP (20 kDa and 29 kDa, respectively; Figure 14A). Unexpectedly, anti-Flag
and anti-GFP western blot analysis did not readily detect the expression of Env fusion proteins,
irrespective of the presence of HIV Rev (Figure 14B). Env-VN-Flag and Env-eGFP expression
was also investigated by immunofluorescence microscopy in HeLa cells by immunostaining for
the HIV-1 Env gp120 region. The expression of Env-VN-Flag and Env-eGFP was undetectable
(Figure 14C). The F2AXNef-GFP construct was utilized as a positive control for Env expression
and demonstrated proper Env expression and immunostaining (Figure 14C). Interestingly, low
levels of GFP expression, as depicted by the white arrow in the Env-eGFP image, were seen at
low frequency. Altogether, these results suggest that construction of Env-VN-Flag and Env-eGFP
fusion proteins required further modifications for expression.

Since the Env-VN-Flag and -eGFP fusion proteins did not correctly express, we generated
alternative constructs by cloning the open reading frames of the HIV rev, vpu, and env genes in
frame with either VN-Flag or eGFP. These additional genes, HIV rev and vpu, were included as
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HIV Rev enhances Env expression through enhanced mRNA export, and HIV Vpu enhances
proper Env folding through degradation of CD4 in the endoplasmic reticulum102,103. Additionally,
we also included either a flexible or rigid 12 amino acid linker sequence between Env and the
protein tag. Linker sequences have been shown to aid in proper fusion protein expression and
function91. 91. A schematic depicting the construction of these constructs is shown in Figure 14.
HEK-293T cells were transfected with these constructs and expression was analyzed via anti-Env,
anti-Flag, and anti-GFP western blots. Two bands with anti-Env reactivity were detected for each
sample, one at ~120 kDa, consistent with gp120, and one at ~180kDa, consistent with the fusion
of the 160kDa gp160 protein with the 20 kDa VN-Flag or 29 kDa eGFP proteins (Figure 16A).
Anti-Flag blots revealed bands at ~60kDa and ~180kDa, consistent with gp41 and gp160 fused to
VN-Flag, respectively. Additionally, anti-GFP blots revealed bands at ~75kDa and ~180kDa,
consistent with gp41 and gp160 fused with eGFP, respectively.

To further confirm construction and proper function of the Env-F/R-VN-Flag and Env-F/R-eGFP
(F; flexible linker, R; rigid linker) fusion proteins, we performed immunofluorescence microscopy.
HeLa cells were transfected with Env-F/R-VN-Flag and Env-F/R-eGFP constructs, cells were
fixed, and Env expression was analyzed. Immunofluorescent analysis revealed that NL4-3 Env
fusion proteins containing a flexible linker sequence had similar cellular distributions when
compared with wildtype NL4-3 Env as reported in the literature, whereas, Env fusion proteins
containing a rigid linker sequence had tight localization surrounding the nucleus (Figure 16)90.
Altogether, these results suggested that the inclusion of HIV rev, vpu, and env genes with a long
flexible linker sequence aids in the successful production and cellular distribution of Env fusion
proteins.
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Figure 14. Investigating the expression of Env-VN-Flag and Env-eGFP fusion proteins. HEK293T cells were transfected with Env-VN¬-Flag or Env-eGFP with or without pRSV-Rev (HIV
Rev). Twenty-four hours post-transfection cell lysates were collected and Env expression was
analyzed by (A) anti-Env (B13 Ab), (B) anti-Flag, or anti-GFP Western blot. β-actin served as a
loading control. (C) Representative immunofluorescent images of HeLa cells transfected with
F2AXNef-GFP, Env-VN-Flag, and Env-eGFP constructs. Env was immunostained using an antigp120 (B12) primary Ab and Alexa647 conjugated secondary Ab for all samples. The white arrow
in the Env-eGFP image highlights low levels of GFP expression. The representative image of EnveGFP is a merge of the GFP and Alexa647 (Env) channels, whereas, the other two images is only
the Alexa647 channel. Specifically, the GFP channel was not shown for F2AXNef-GFP due to the
high expression of Nef-GFP which would have made it difficult to visualize expression of Env in
the Alexa647 channel. All experiments were conducted a minimum of two times (N=2).
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Figure 15. Construction of HIV NL4.3 Rev-Vpu-Env-VN-Flag/eGFP expression vectors. The
HIV NL4-3 rev, vpu, and env genes were co-amplified by PCR and then cloned into pN1-VN¬Flag and pN1-eGFP backbones. The reverse primer overhang contained either a flexible or rigid
linker sequence located in the region depicted in red (*).
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Figure 16. Extended linker sequence length and expression of HIV Rev, Vpu in cis improves
expression of Env-F/R-VN-Flag and Env-F/R-eGFP fusion proteins. (A) HEK-293T cells were
transfected with constructs encoding Env-F/R-VN-Flag or Env-F/R-eGFP (F; flexible linker, R;
rigid linker). Twenty-four hours post-transfection cell lysates were collected and Env fusion
protein expression was analyzed by anti-Env (B13 Ab), anti-Flag, and anti-GFP western blots. βactin served as a loading control. (B) Representative immunofluorescent images of HeLa cells
transfected with Env-F/R-VN-Flag and Env-F/R-eGFP constructs. Env-F/R-VN-Flag was
immunostained using an anti-Flag primary Ab and Alexa647 conjugated secondary Ab.
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3.9 Env-F/R-VN-Flag and Env-F/R-eGFP fusion proteins retain
membrane fusion capability
The construction of fusion proteins involves the addition of large protein fragments to the C- or
N-terminus of a protein and may affect wild-type protein function. Therefore, to further confirm
proper function of the Env-F/R-VN-Flag and Env-F/R-eGFP fusion proteins, we investigated their
ability to: 1) mediate cell-cell fusion, and 2) be incorporated into HIV pseudoviruses and permit
infection of target cells. First, HeLa cells were transfected with the Env-F/R-VN-Flag and EnvF/R-eGFP constructs and Tat expression vector and after twenty-four hours were mixed with the
TZM-bl reporter cell line to measure cell-cell fusion. Cell-cell fusion of all four Env fusion proteins
was significantly greater than the pTat only control (Figure 17A).

Next, we tested the ability of the Env fusion proteins to be incorporated into HIV pseudovirus
particles and mediate infection. HEK-293T cells were co-transfected with the Env-F/R-VN-Flag
or Env-F/R-eGFP constructs and the proviral SG3 ΔEnv vector to produce pseudotyped HIV
particles. Pseudovirus containing supernatant was then titrated onto TZM-bl cells and the level of
infectivity was measured. Reported as relative light units, all Env fusion proteins resulted in
detectable infectivity of TZM-bl cells (Figure 17B). Overall, these findings confirm proper
functionality of the generated Env fusion proteins and support their application in current and
future immunofluorescence experiments.
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Figure 17. Env-F/R-VN-Flag and Env-F/R-eGFP fusion proteins retain functionality. (A)
HeLa cells were co-transfected with pTat and Env-F/R-VN-Flag or Env-F/R-eGFP expression
vectors. Cell-cell fusion was measured indirectly using the Galacto-star assay kit (N=3). ****
P<0.0001, * P<0.05. One way ANOVA with Dunnett’s multiple comparisons test was used to
determine statistical significance. (B) HEK-293T cells were co-transfected with SG3ΔEnv and
Env-F/R-VN-Flag or Env-F/R-eGFP expression vectors and 48 hours later supernatant containing
pseudovirus was filtered and titrated onto TZM-bl cells. Relative light emission of HIV
pseudovirus infection at various dilutions was measured indirectly using the Galacto-star assay
with background light emission subtracted. The relative light emission for the 2-fold dilution of
pseudovirus is shown (N=2).
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3.10 Bimolecular fluorescence complementation microscopy detects a
Nef:Env interaction
With the successful generation of an Env BiFC construct, we next performed a BiFC assay to
determine if the HIV-1 Env and Nef proteins are in close proximity. Since the Env-F-VN-Flag
fusion protein had a cellular distribution most similar to wildtype Env, it was utilized for BiFC
analyses. Co-transfection of HeLa cells with plasmids encoding Nef-VC-V5 and Env-F-VN-Flag,
more specifically Nef and Env fused to carboxy (VC) or amino (VN) fragments of the Venus
fluorophore, respectively, revealed a positive BiFC signal for Nef and Env(Figure 18). As a BiFC
positive control, Nef-VC-V5 and MHC-I-VN-Flag were co-transfected into HeLa cells93. Next, we
tested the effect of various Nef mutants on the complex formation of Env:Nef via BiFC.
The use of well-characterized Nef mutants may allow us to determine which cellular proteins Nef
utilizes to complex with Env. As outlined in Chapter 1, the Nef-AxxA and E4A mutants prevent
interaction of Nef with Pak2 or SH3 domains and the PACS proteins, respectively, whereas, the
DD/GA and LL/AA Nef mutants prevent interaction with the adaptor protein complex family
members63. Co-transfection of plasmids encoding Nef-AxxA-VC, -E4A-VC, -DD/GA-VC, or LL/AA-VC and Env-F-VN-Flag into HeLa cells appeared to result in a decrease in the BiFC signal
relative to wild type Nef (Figure 18). These preliminary results suggest that Env and Nef may
interact either directly or in a complex. Additionally, our results indicate that Nef:Env complex
formation may require Nef’s ability to interact with Pak2, SH3 domains, PACS proteins, and the
adaptor protein complex family members.
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Figure 18. Bimolecular fluorescence complementation is observed between Env and Nef.
Left: Schematic representation of the BiFC reporter system. Within close proximity the split
halves of the Venus fluorophore (VC and VN) reconstitute and fluoresce (depicted by the yellow
colour). Right: Representative images of Env-F-VN-Flag and either wildtype (wt) Nef-VC-V5 or
the indicated mutants were transfected into HeLa cells. Twenty-four hours post-transfection cells
were fixed and BiFC fluorescence (green) was observed under the FITC channel. Nef-VC and
MHC-I-VN-Flag BiFC was utilized as a positive BiFC control.
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Chapter 4

4

Discussion

HIV-1 represents one of humanity’s greatest challenges. With the absence of a cure, the number
of infected individuals continues to rise. Although anti-retroviral therapy can slow the progression
of HIV infection to AIDS, the limited availability of ART can be challenging for those living in
underdeveloped countries. As a result, prevention of initial infection through vaccination remains
an ideal goal. Despite numerous efforts, no HIV vaccine has been able to provide meaningful
protection in human clinical trials65–68, The IAVI VSV-based HIV vaccine, VSVΔG-Env.BG505,
has shown promise in preclinical studies. However, this vaccine generated limited anti-Env Abs,
which are critical for viral neutralization. Additionally, the IAVI VSV-based HIV vaccine did not
provide any correlates of protection80,86. Furthermore, the trafficking of HIV Env to sites of viral
assembly is poorly understood. The HIV Nef protein may play a role in modulating HIV Env
trafficking as it is a master trafficking regulator of many cell surface proteins54. Furthering our
understanding of Env trafficking may provide additional insights for the design of an effective
HIV vaccine.
In this study, we tested the inclusion of the EBOV GP gene within the IAVI VSV construct and
aimed to generate and characterize new chimeric HIV-1 Env proteins that have enhanced
expression and immunogenicity on the VSV vaccine platform. To this end, we showed that it is
possible to co-pseudotype VSV with a chimeric HIV Env protein and EBOV (Figure 8). We also
observed that our codon-optimized chimeric Env immunogens, which contain the signal sequence
of the honeybee melittin protein and the transmembrane and cytoplasmic tail domains of SIV Env,
Zaire Ebola, or VSV glycoproteins, retain viral entry functionality and have high levels of
expression within producer cells (Figures 10, 11). Furthermore, these COA74 Env chimera had
enhanced levels of incorporation in rVSV particles. The apparent expression level differences,
presumably mediated by Env trafficking pathways, led us to further investigate the involvement
of HIV-Nef in the trafficking of Env to sites of viral assembly (Figure 9). Importantly, we
identified a potential Env:Nef complex, which was disrupted by well-characterized Nef mutants
(Figure 18). This process was established utilizing a bimolecular fluorescence complementation
assay for intracellular protein-protein interactions.
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4.1 Alternative VSV vector construction and Env chimera design and
characterization
Importantly, because the mechanism by which the VSVΔG-Env.BG505 vaccine conferred
protection in NHPs remains to be determined, it is plausible that protection was an indirect result
of CD4+/CCR5+ cell depletion from in vivo vector replication. Therefore, we aimed to broaden
the cellular tropism of our VSV-based HIV vaccine beyond CD4+/CCR5+ cells by copseudotyping VSV particles with EBOV GP and a chimeric Env protein. Our results confirm the
ability to co-express EBOV GP and a chimeric HIV Env on VSV particles. This was expected as
VSV particles are easily pseudotyped by other viral glycoproteins, including those of hepatitis C
virus, influenza virus, or EBOV GP (rVSVΔG-EBOV vaccine)73,77,78. Interestingly, although the
incorporation level of HIV-1T713 was lower in the presence of EBOV GP compared to VSV-G,
mice immunized with rVSVΔG-EBOV-NL4-3T713 had significantly higher serum levels of antiEnv IgG Abs versus rVSVG-NL4-3T713 (Figure 8A-C). This may be a result of the EBOV GP
targeting the infection of antigen-presenting cells such as macrophages and dendritic cells, which
may accelerate the maturation of T helper cells and B cell activation89,104. Alternatively, the ability
of EBOV GP to antagonize the host membrane protein tetherin, which inhibits the release of
enveloped viruses including VSV, may have enabled enhanced replication and immune activation
in mice105,106. These results support the inclusion of the EBOV GP gene alongside novel chimeric
HIV Env genes for immunogenicity testing in mice, rabbits, and for protection against SHIV
challenge virus in NHPs. In addition to broadening the cellular tropism of our vector, coexpression of EBOV GP and a chimeric HIV immunogen may provide protection against both
EBOV and HIV, a desirable quality for individuals in Africa and Asia where both EBOV and HIV
are present4,107.

The production of chimeric proteins is a powerful technique utilized in many facets of research.
As seen with the VSVΔG-Env.BG505 vaccine, chimeric proteins often require further
optimization. Here, we demonstrate the generation of novel chimeric HIV-1 Env proteins
containing the TM + CT of SIVmac239 Env or EBOV GP, which can efficiently pseudotype VSV
particles in the presence of full-length EBOV GP. We have shown for the first time the
incorporation of chimeric Env proteins containing the TM + CT of SIV Env onto VSV particles.
Truncated SIV Env has been previously shown to be expressed at high levels on the cell surface
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in tightly packed patches, which lead to efficient incorporation into budding VSV particles82. As
expected, the Env chimera containing the TM + CT of EBOV GP were efficiently incorporated
into VSV particles, similarly to wildtype EBOV GP. Although NL4-3/SIV TMshCT and NL43/EBOV GP TMCT Env chimera equally pseudotyped VSV-EBOV GP particles, their
immunogenicity may differ. Multiple studies have shown that deletions of the HIV gp41 CT can
alter the conformation of the extracellular gp120 regions to the point of altering
immunogenicity108,109. However, due to the high degree of structural similarity between HIV and
SIV Env proteins, the native conformation of NL4-3 Env and relevant immunogenic epitopes may
be better maintained in NL4.3/SIV TMshCT110. To investigate this, future studies will analyze the
anti-HIV Env Abs response (including neutralizing, ADCC, and phagocytosis activities) against
rVSV-EBOV particles expressing NL4-3/SIV TMshCT or NL4-3/EBOV GP TMCT in mice or
rabbits.

We have also shown that codon optimized A74 Env chimera containing the honeybee melittin
signal peptide and TM + CT of SIV Env (truncated), EBOV GP, or VSV-G have high expression
within and on the surface of producer cells in the context of the pcDNA3.1 expression vector, as
measured via western blot and flow cytometry, respectively. Initially, unmodified HIV-1 A74/SIV
TMCT and A74/EBOV TMCT chimeras inefficiently pseudotyped rVSV-EBOV particles, which
prompted their optimization for enhanced expression. Low incorporation of A74 Env chimeras
versus NL4-3 Env chimeras into rVSV may have been due to lower protein expression of the A74based Env chimera. Evidence to support this was obtained from our transfection analysis. Although
investigated in the context of pcDNA3.1 vectors, and not the rVSVΔG-EBOV construct, chimeric
NL4-3/SIV TMCT but not NL4-3/EBOV GP TMCT was expressed at significantly higher levels
than A74 Env chimeras. An analysis of the A74 and NL4-3 gp120 coding sequences using
GenScript’s rare codon analysis tool revealed that while the codon usage bias of both A74 and
NL4-3 were similar (0.67 and 0.69), the A74 gp120 sequence contained three times as many
negative cis regulatory elements known to reduce transcription efficiency. Codon optimization of
HIV-1 Env has previously been shown to remove negative cis regulatory elements to enhance
protein expression111,112. In addition to codon optimization, we also replaced the HIV Env signal
peptide with the signal peptide of honeybee melittin in an effort to further enhance expression of
A74 Env chimera. The HIV Env signal peptide has been shown to slow protein folding and
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expression, whereas, the replacement with an efficient signal peptide, such as that of honeybee
melittin, greatly enhances cell surface expression84,111. A potential limitation is that altering the
signal peptide of HIV Env has been shown to alter glycosylation of Env113. This could potentially
enhance immunogenicity as glycans cover many key neutralization epitopes, or negatively affect
Env immunogenicity, as certain glycans are important for Env structure, or make up immunogenic
epitopes25,114. A limitation of our study was that we did not explicitly measure differences in
mRNA levels between NL4-3 and A74 Env chimeras. Future studies will utilize qRT-PCR to
investigate potential differences in construct steady state mRNA levels. Analysis of rVSV particles
showed that codon optimization and inclusion of the honeybee melittin signal peptide enhanced
incorporation of the A74 Env chimera in rVSV particles. Unexpectedly, it appeared that codon
optimization alone was sufficient to enhance incorporation of A74 Env chimera containing the
SIV TMshCT, whereas, both codon optimization and the Hb-SP were required to greatly enhance
incorporation of EBOV TMCT A74 Env chimera. These differences suggest that the EBOV GP
TMCT contain elements which inhibit expression both at translation and post-translationally.
Unfortunately, our experiments did not test the effect of the Hb-SP alone, which serves as a future
goal. Regardless, Wang et al showed that codon optimization and signal peptide exchange both
play individual roles in enhancement of Env expression, thus, it is likely that in the generation of
novel Env chimera, all Env modifications likely require empirical testing111. Overall, rVSVΔGEBOV particles with enhanced levels of A74 Env chimera through codon optimization and/or
inclusion of the Hb-SP need to be investigated for potentially enhanced immunogenicity in mice.

Our study design for characterizing and comparing COA74, NL4-3, and A74 Env chimeras had
limitations that need to be addressed. First and foremost, more experimental repeats are needed to
validate our cell surface expression and cell-cell fusion results. Additionally, western blot and flow
cytometry analyses for Env chimera expression were conducted utilizing two different cell types,
HEK-293T and HeLa cells, respectively. Although both 293T and HeLa cells are used in HIV
research, Geiger et al (2012) have shown that these cell types have varying expression of many
different cellular proteins, which may affect our results115. Therefore, for consistency, future
experiments characterizing chimeric Env proteins in the context of pcDNA3.1 will be conducted
in HEK-293T cells as they are easily transfectable and the main cell type used for producing HIV
particles116. Furthermore, VSV replicates within the cytoplasm and thus Env chimera mRNA does
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not require HIV Rev for nuclear export for high expression. However, because we characterized
the Env chimeras in the context of pcDNA3.1 vectors, the A74 and NL4-3-based Env chimeras
required the presence of Rev for mRNA nuclear export. The requirement for Rev was realized
after completion of flow cytometric analysis of Env chimera expression, thus flow cytometry
expression levels of A74 and NL4-3-based chimera is in the absence of Rev. It is important to note
that our COA74 Env chimeras were not co-transfected with Rev because their expression was
determined to be Rev-independent by western blot analysis, which is supported by Vinner et al
(1999)112. Lastly, more controls are needed in future experiments. While pREC.nfl.NL4-3, a
replication-incompetent vector which expresses all the HIV proteins was utilized as a comparison
for total expression by western blot, a better control would have been a construct expressing only
wildtype NL4-3 or A74 Env, so that expression would be in the absence of the other HIV proteins.
Ideally, we would like to directly compare our chimeric HIV-1 Env proteins alongside the IAVI’s
VSVΔG-Env.BG505 vaccine candidate.

4.2 Investigating the role of Nef in HIV Env trafficking
The production of fluorescently tagged Env fusion proteins for use in colocalization and BiFC
experiments required optimization for proper expression. Initial Env-VN-Flag and Env-eGFP
fusion proteins were detected at low levels using an anti-Env western blot analysis and only in the
presence of HIV Rev. Unexpectedly, fusion protein expression was undetectable by anti-Flag and
anti-GFP western blots. Poor expression and the inability to detect samples may have been a
combination of improper mRNA exportation and protein folding91,102. These results were
unexpected but provided useful information for the improvement of fusion protein expression.
First, Rev co-expression enhanced fusion protein expression due to its ability to enhance and
stabilize RRE containing env mRNA nuclear exportation102. Therefore, rather than only clone HIV
env, we constructed a vector encoding the open reading frames of HIV rev, vpu, and env. The open
reading frame of HIV vpu was included as it is present between rev and env; however, Vpu
downregulation of CD4 present in the ER will prevent interactions of Env and CD4 and represent
a more biologically relevant situation103. Second, because Rev-mediated enhancement of fusion
protein expression was modest, this suggests that additional roadblocks exist, a common one for
fusion proteins is issues with protein folding due to a suboptimal linker region. Although the short
linker we used (LPVAT) may work for some fusion proteins, an overview of fusion protein linkers
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by Chen et al (2013) supports the empirical testing of longer linkers with different properties.
Therefore, we utilized 12 amino acid long linkers with either flexible or rigid properties 91. These
second generation constructs expressed well by western blot and were shown to retain functionality
in a cell-cell fusion assay. Fusion proteins containing the flexible linker region had proper Env
cellular distribution. Unexpectedly, those with a rigid linker had a perinuclear localization.
Therefore, as suggested by Kerppola (2006), the linker may alter cellular interactions affecting
localization, hence the importance of empirical testing and validation101. Therefore, constructs
encoding for HIV Vpu, Rev, and Env-VN and -eGFP fusion proteins connected with flexible linker
sequences were verified for expression and utilized for BiFC and fluorescent microscopy studies.

Using a BiFC assay, we provide evidence for the formation of a HIV-1 Env:Nef complex in cellulo.
While the subcellular localization of the Env:Nef complex remains to be determined, our
independent immunofluorescence experiments reveal a high degree of colocalization of Env and
Nef within the TGN. Our result suggests the formation of a potential multiprotein complex
including Env and Nef within the TGN. Previous studies have revealed the involvement of AP-1
in Env trafficking in the TGN, as well as the interaction of AP-2 and Env within endosomes46,47.
Furthermore, Nef prevents recycling of MHC-I to the plasma membrane or induces MHC-I
endocytosis within AP-1 coated endosomes by interaction with AP-1, and downregulates CD4 via
AP-2 interactions64,117. Therefore, a tertiary complex involving Nef, Env, and AP-1/AP-2 may be
involved in enhanced Env trafficking to the PM or retention in early endosomes. To further validate
Env:Nef complex formation and investigate potential motifs of Nef involved in this interaction,
we utilized well-characterized Nef mutants and determined their effect on Env:Nef BiFC signal.
Interestingly, the Env:Nef BiFC signal was diminished with the Nef-E4A mutant. The Nef-E4A
mutant has been shown to inhibit Nef’s ability to interact with PACS-1 and PACS-2118. The
interaction with PACS-2 recruits Nef to the TGN for the initiation of a signaling cascade that
internalizes of cell surface MHC-I molecules53. Thus, interaction with PACS-2 may be required
for the localization of Env in the TGN for complex formation. Subsequent to the initiation of
signaling by the Nef-PACS-2 interaction, the interaction with PACS-1 allows Nef to interact with
AP-1 in early endosomes and sequester MHC-I to the TGN52. Thus, Nef may utilize PACS-1 and
AP-1 for the intracellular retention of Env. The Nef-AxxA mutant, which inhibits interaction of
Nef with SH3 domain containing proteins after recruitment by PACS-2 to the TGN, also inhibited
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Env:Nef complex formation119. This Nef mutant is unable to initiate a signal transduction pathway
for the cell surface downregulation of MHC-I via Arf6; however, it is uncertain how the abrogation
of Nef and SH3 domain containing proteins would affect its complex formation with Env.
Interestingly, the LL164/165AA and DD174/175AA Nef mutants, which are deficient in their
abilities to interact with the AP complex proteins, diminished the Env:Nef BiFC signal50,120. This
supports a potential multiprotein complex between Env, Nef, and AP-1/-2, however, whether this
complex enhances trafficking of Env to the PM or retains Env intracellularly is unknown. Due to
time constraints, the expression levels of Nef mutants used in BiFC analysis were not compared
relative to wildtype Nef. Therefore, the extinguished Env:Nef BiFC signal using the Nef mutants
may simply be a result of reduced expression. Future steps will assess the expression levels of the
Nef mutants, and our experiments will be adjusted to ensure equal expression of the mutants with
wildtype Nef. Additionally, more experimental repeats are essential to validate our results. A
potential limitation of our experimental design is the absence of the other HIV-1 proteins that are
normally expressed in the HIV replication cycle, which could affect the localization or strength of
the detected Env:Nef complex formation. For example, the interaction of HIV Gag with the Env
cytoplasmic tail has been shown to prevent endocytosis. Thus, the localization of Env may be
different in a more biologically relevant system121. To address this, as demonstrated by Zhang et
al (2019), BiFC tagged Env and Nef proteins could be cloned into the NL4-3 backbone to allow
investigation of their interaction in the presence of all the HIV-1 proteins122.

4.3 Future directions
In the future, we aim to investigate the immunogenicity of our COA74 Env containing rVSVΔGEBOV particles within mice. Our vaccine candidates will also be tested in rabbits so enough sera
can be collected to further characterize the anti-HIV Env Ab response with regards to neutralizing,
ADCC, and phagocytosis Ab activities. The most promising candidates will then be tested in an
NHP model of infection, with the hopes of optimizing the induction of a protective humoral
response. Our study focused on generating and optimizing chimeric Env immunogens for high
expression in a VSVΔG-EBOV vector for the induction of a protective anti-HIV humoral
response; however, a successful HIV vaccine may require elicitation of both humoral and cellular
mediated immunity for significant protection. Therefore, the SIV gag gene will be introduced into
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our rVSVΔG-EBOV-Env constructs with the hopes of inducing an anti-Gag cytolytic CD8+ T cell
response.

Future directions also include elucidating the composition of the potential of multiprotein complex
involving HIV Env and Nef and what role it plays in the HIV Env trafficking pathway.
Specifically, after localizing the Env:Nef complex, we plan to utilize an EnvΔCT-VN mutant to
determine if the interaction is dependent on the Env cytoplasmic tail. Additionally, the role of AP1 and AP-2 will be investigated by immunofluorescence microscopy and by siRNA knockdown
studies. Lastly, co-immunoprecipitation will be utilized to investigate if a direct Env:Nef
interaction can be detected.

4.4 Conclusion
Overall, we have generated novel, well expressed chimeric Env proteins for testing within a novel
VSVΔG-EBOV-HIV.Env vaccine platform. These vaccine candidates have been designed with
the goal of producing a multi-faceted anti-HIV humoral response, which has not yet been
accomplished by any HIV vaccine tested in clinical trials. Furthermore, our study provides the first
evidence of an Env:Nef complex in vitro, which supports the potential involvement of Nef in the
Env trafficking pathway. Further studies will explore the nature of this complex, which may
elucidate mechanisms to enhance Env expression for HIV vaccine design. In conclusion, the need
for an effective HIV vaccine cannot be understated and our findings represent another step towards
the realization of this endeavor.
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Appendices

A

B

Supplementary Figure 1. (A) Schematic representation of the chimeric COA74 Env chimeras
tested in the presence or absence of HIV-1 Rev. HEK-293T cells were transfected and twenty-four
post-transfection were analyzed for Env expression by western blot. (B) Western blot analysis of
COA74 Env chimera expression normalized by β-Action (N=1).
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